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Zusammenfassung  
Das in Europa vorkommende Dobravavirus (DOBV) wird durch zwei 
unterschiedliche Nagetierwirte, die Gelbhalsmaus Apodemus flavicollis und die 
Brandmaus A. agrarius, übertragen. DOBV kann bei humanen Infektionen zum 
Auslösen eines "Hämorrhagischen Fiebers mit renalem Syndrom" (HFRS) 
unterschiedlicher Schweregrade führen. Wie alle Hantaviren ist das DOBV ein 
umhülltes Virus, das in seiner Hülle die Glykoproteine G1 und G2 trägt. Im Inneren 
der Viruspartikel befinden sich die drei mit Nukleokapsid (N) Protein assoziierten 
Negativstrang-RNA Genomsegmente, sowie die RNA-abängige RNA-Polymerase.  
Das N Protein von Hantaviren ist stark immunogen, sowohl in natürlich 
vorkommenden Infektionen von Menschen als auch in natürlichen und 
experimentellen Infektionen von Nagetieren. Des weiteren rufen Impfungen von 
Nagetieren mit N Protein eine starke N-spezifische Immunantwort hervor. Eine 
Impfung mit rekombinanten N Protein Derivativen schützt in Nagetiermodellen vor 
einer Hantavirusinfektion. Dies konnte unter anderem für chimaere Hepatitis B 
Virus (HBV) Corepartikel und das komplette rekombinante N (rN) Protein gezeigt 
werden. 
In der vorliegenden Arbeit wurde die Immunogenität von zwei auf dem DOBV N 
Protein basierende Protein Derivativen in Mäusen getestet. Zum einen wurden in 
E. coli exprimierte chimaere HBV Corepartikel verwendet, die von verkürztem 
Core-(HBcd)-Protein gebildet wurden, das die 120 amino-terminalen Aminosäuren 
(AS) des DOBV N Proteins trugen (HBcdDOB120). Das zweite Protein, komplettes 
DOBV rN Protein (429 AS), wurde in Hefen exprimiert. Anschließend wurden 
BALB/c (H2-d) und C57BL/6 (H2-b) Mäuse dreimal subkutan mit 50 μg 
HBcdDOB120 oder DOBV rN Protein in komplettem Freund's, inkomplettem 
Freund's und anschliessend ohne Adjuvants immunisiert. Für die Immunisierungen 
wurde ein Schema verwendet, mit dem bereits das Potential verschiedener 
Hantavirus Impfstoffkandidaten im Nagetiermodell getestet wurde. Vor jeder 
Impfung, sowie zwei Wochen und 29 Wochen nach der dritten Impfung wurde der 
N-spezifische Antikörpertiter im Serum bestimmt.  
Sowohl BALB/c, als auch C57BL/6 Mäuse entwickelten eine starke N-spezifische 
Antikörperantwort nach Impfung mit sowohl HBcdDOB120, als auch nach Impfung 
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mit DOBV rN-Protein, mit maximalen Titern von über 1:1.000.000. Die 
Antikörperantwort war langanhaltend und N-spezifische Titer waren 29 nach der 
dritten Impfung mit HBcdDOB120 und DOBV rN Protein immer noch höher als 
1:35.000 in allen Mäusen. Beide Proteine induzierten Antikörper, die eine starke 
Kreuzreaktivität gegenüber den rN Proteinen der Hantaviren Puumala, Hantaan, 
Andes und Sin Nombre aufwiesen.  
HBcdDOB120 und DOBV rN-Protein induzierten in BALB/c und C57BL/6 Mäusen 
N-spezifische Antikörper aller Subklassen (IgG1, IgG2a, IgG2b und IgG3), was auf 
eine gemischte Th1/Th2 Antwort schließen lies. Ebenfalls auf eine gemischte 
Th1/Th2 Immunantwort deuteten die N-spezifischen IFN-γ und IL-4 sekretierenden 
Lymphozyten von HBcdDOB120 oder DOBV rN Protein immunisierten Tieren nach 
in vivo Restimulierung. Die Frequenz der durch die Immunisierungen induzierte N-
spezifischen Lymphozyten war allerdings gering.  
Auch in Mäusen, die hohe HBc-spezifische Antikörpertiter aufwiesen konnte eine 
starke N-spezifischen Immunantwort mittels Impfung mit HBcdDOB120 induziert 
werden. Das heisst, auf chimären Core Partikel basierende Impfstoffe sollten 
selbst in anti-HBc-positiven Individuen nach einer HBV Infektion wirksam sein.  
HBcdDOB120 und Hefe-exprimiertes DOBV rN Protein stellen vielversprechende 
Vakzinekandidaten dar, die auf ihre Protektivität hin getestet werden sollten, 
sobald ein DOBV Infektionsmodell verfügbar ist. Da HBcdDOB120 sowie DOBV rN 
Protein eine starke Antikörperantwort und nur eine schwache T-Zellantwort 
induzieren sollte zusätzlich die Rolle von N-spezifischen Antikörpern im Schutz 
gegen die Virusinfektion weiter charakterisiert werden. 
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Summary 
In Europe, the human pathogenic Dobrava virus (DOBV) is carried by the yellow-
necked mouse Apodemus flavicollis and the stiped field mouse A. agrarius and 
causes "haemorrhagic fever with renal syndrome" of different severity in humans. 
Like other hantaviruses, DOBV is an enveloped virus with the glycoproteins G1 
and G2 embedded in the envelope. Inside the virions are the RNA-dependent 
RNA-polymerase and the three negative-strand RNA segments which are 
associated with the nucleocapsid (N) protein. 
The N protein is very immunogenic in natural infections of humans and in natural 
as well as experimental infections of rodents. Even immunisations of rodents with 
N protein induces a strong N-secific immune response. Moreover, immunisation 
with N protein derivatives could protect rodents from a hantavirus infection. This 
was shown for several derivatives, including chimeric hepatitis B virus core (HBc) 
particles and entire recombinant N (rN) protein. 
In this study, the immunogenicity of the two following derivatives based on the 
DOBV N protein was tested in mice. Chimeric HBV core particles, consisting of 
truncated HBc (HBcd) particles carrying the amino-terminal 120 amino acids (aa) 
of the DOBV N protein (HBcdDOB120) were expressed in E. coli. The second 
derivative, the entire DOBV rN protein (429 aa) was expressed in the yeast 
Saccharomyces cerevisiae. Hence BALB/c (H2-d) and C57BL/6 (H2-b) mice were 
immunised subcoutanously three times with 50 μg HBcdDOB120 or DOBV rN 
protein in complete Freund's, incomplete Freund's and without adjuvant, 
respectively. The immunisations were thereby identical to the immunisation sheme 
used previously in a hantavirus challenge model. Before each immunisation as 
well as two and 29 weeks after the last immunisation N-specific antibody titers in 
the serum were determined. 
Mice of both strains elicited strong N-specific antibody responses after 
HBcdDOB120 as well as after DOBV rN protein immunisation, with endpoint titers 
as high as 1:1,000,000. The antibody response was long-lived and N-specific titers 
were above 1:35,000 in all mice 29 weeks after the third immunisation with either 
derivative. Both derivatives induced antibodies that were highly cross-reactive to 
the rN proteins of the hantaviruses Puumala, Hantaan, Andes and Sin Nombre.  
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HBcdDOB120 and DOBV rN protein induced in BALB/c and C57BL/6 mice N-
specific antibodies of all IgG subclasses (IgG1, IgG2a, IgG2b and IgG3)  
suggesting a mixed Th1/Th2 immune response. In the same line, IFN-γ and IL-4 
was secreted by N-specific lymphocytes from mice immunised with HBcdDOB120 
or DOBV rN protein after in vitro restimulation which also indicated a mixed 
Th1/Th2 response. However, the frequency of N-specific lymphocytes that were 
induced by HBcdDOB120 and DOBV rN protein seemed to be low. 
In mice that exhibited a high HBc-specific antibody titer HBcdDOB120 induced a 
strong N-specific immune response. Therefore, vaccines based on chimeric HBcd 
particles will probably be effective even in anti-HBc positive individuals after HBV 
infection.  
HBcdDOB120 and yeast-expressed DOBV rN protein represent a promising 
vaccine candidate that should be tested for their protective potential in an DOBV 
challenge model as soon as one gets available. Additionally, as protection might 
be partially based on N-specific antibodies, their role in protecting against a 
hantavirus infection should be characterised further. 
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1 Introduction 
1.1 Structure of hantaviruses 
Hantaviruses are spherical, enveloped RNA viruses with a diameter of 78-210 nm 
and belong to the family of Bunyaviridae [reviewed in Schmaljohn, 96]. Their 
genome consists of three segments of negative-sense, single-stranded RNA that 
code for three proteins. The large (L) segment encodes the RNA-dependent RNA 
polymerase (RdRp) and the small (S) segment the nucleocapsid (N) protein. The 
medium (M) segment codes for the glycoprotein precursor which is cleaved by a 
cellular protease into the two glycoproteins G1 and G2. 
In contrast to other genera of Bunyaviridae, nonstructural proteins have not been 
described for hantaviruses. However, almost all hantaviruses associated with 
rodents from the subfamilies Arvicolinae and Sigmodontinae have a second open 
reading frame (ORF-2) on the S segment [Ulrich, 02]. Murinae associated 
hantaviruses do not have a second ORF on the S segment. If this second ORF of 
the Arvicolinae and Sigmodontinae associated hantaviruses, which encodes for a 
putative 60 – 90 amino acid (aa) long protein, is expressed in infected cells 
remains to be elucidated. Presence or absence of this second ORF on the S 
segment does not seem connected to the virulence of the viruses to humans, but 
might be relevant for the adaptation of the hantavirus to its rodent hosts.  
Maturation of the majority of viruses from genera in the family of Bunyaviridae 
occurs intracellular by budding into the Golgi cisternae [Kuismanen, 85; Ellis, 88; 
Hobman, 93; Rwambo, 96; Jantti, 97]. Budding virus particles were found in the 
Golgi compartment in endothelial cells of patients with an epidemic haemorrhagic 
fever in China that was most probably caused by members of the Bunyaviridae 
family [Wang, 97]. Therefore, maturation of the hantavirus virions was thought to 
take place mainly at the Golgi compartment. In contrast, Sin Nombre virus (SNV) 
and Black Creek Canal virus, both members of the New World hantaviruses, have 
been found to bud predominantly at the plasma membrane [Goldsmith, 95; 
Ravkov, 97]. These controversial findings show that further investigations are 
needed to precisely identify the site and mechanism of budding for the different 
hantaviruses [Spiropoulou, 01].  
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FIGURE 1: Schematic drawing of a hantavirus particle. Hantaviruses are enveloped 
negative-strand RNA viruses. The virus particle consists of an RNA-dependent RNA-polymerase 
(RdRp), two glycoproteins (G1 and G2) and the nucleocapsid (N) protein encoded by the three 
RNA segment, the large (L), the medium (M) and the small (S) segment, respectively. The RNA 
segments are associated with the N protein. 
 
1.2 Geographic distribution and natural hosts of hantaviruses 
Hantaviruses, in contrast to the other, arthropod borne genera of the Bunyaviridae, 
are transmitted by rodents. In these rodents, their natural hosts, they establish a 
persistent infection without causing disease [Meyer, 00; Plyusnin, 01a; Plyusnin, 
01b]. Hantaviruses show a strong host specificity and interspecific spill over seems 
to be a rare event. So far about 25 hantavirus species have been identified that 
are associated with different rodent species (for a selection see Tab. 1).  
The transmission of hantaviruses from rodents to humans is thought to occur 
mainly through aerosols of infected animal excreta, i.e. saliva, urine and faeces. In 
contrast to the Old World hantaviruses, there are indications for person to person 
transmission during an ANDV outbreak in Argentina [Padula, 98] and a series of 
cases in Buenos Aires [Pinna, 04].  
 
1.3 Diseases caused by hantaviruses 
Hantaviruses cause two diseases in humans. Haemorrhagic fever with renal 
syndrome (HFRS), with a case fatality rate of up to 15 % is caused by Old World 
hantaviruses. With a lower frequency then HFRS worldwide, hantavirus 
cardiopulmonary syndrome (HCPS), with a case fatality rate of up to 40 % is 
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caused by New World hantaviruses [for reviews see Schmaljohn, 97; Krüger, 01; 
Ulrich, 02].  
In 1978 it was proven that the hantavirus prototype HTNV was the causative agent 
of KHF, a severe form of HFRS [Lee, 78c]. The virus had been isolated from the 
lungs of an A. agrarius coreae captured in the rural endemic areas of Korean 
haemorrhagic fever (KHF) cases in 1976 [Lee, 78a]. Much earlier however, a war 
nephritits clinically very similar to the milder form of HFRS occuring in Scandinavia 
(nephropathia epidemica, NE, see Tab. 1) had been reported among British 
soldiers stationed in Flanders during World War I [reviewed in Lee, 82a].  
TABLE 1: Natural reservoir and geographical distribution of selected hantaviruses and 
their associated diseases. [Krüger, 01; For a more complete summary of hantaviruses see 
Hooper, 01c; Khaiboullina, 02] 
virus  human
disease 
rodent host  
(subfamily / species) 
distribution reference 
  Murinae    
Hantaan (HTNV) HFRS Apodemus agrarius  
(striped field mouse) 
Asia [Lee, 78b] 
Dobrava (DOBV-Af) 
 
(DOBV-Aa) 
HFRS Apodemus flavicollis  
(yellow-necked mouse) 
Apodemus agrarius 
(striped field mouse) 
Europe [Avsic-Zupanc, 92a] 
[Klempa, 03] 
Seoul (SEOV) HFRS Rattus species 
(rats) 
Asia / 
worldwidea 
[Lee, 82b] 
  Arvicolinae   
Puumala (PUUV) NE Clethrionomys glareolus 
(bank vole) 
Europe [Brummer-Korvenkontio, 
80] 
Tula (TULV) - Microtus species 
(common voles) 
Europe [Plyusnin, 94] 
[Sibold, 95] 
  Sigmodontinae    
Sin Nombre (SNV) HCPS Peromyscus maniculatus 
(deer mouse) 
North 
America 
[Nichol, 93] 
Andes (ANDV) HCPS Oligoryzomys species 
(rice rats) 
Argentina, 
Chile 
[Levis, 97] 
HFRS haemorrhagic fever with renal syndrome; NE nephropathia epidemica; HCPS hantavirus 
cardiopulmonary syndrome 
a SEOV has mostly been found in Asia, but occurs world wide 
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In Europe mainly two hantaviruses have been found to cause HFRS of different 
severity in humans [Mustonen, 98b; Sibold, 99a; Plyusnin, 01a]. PUUV is known to 
cause NE [Brummer-Korvenkontio, 82], with a case fatality rate of up to 0.1 % 
[Lähdevirta, 82]. In south-east Europe DOBV carried by the yellow-necked field 
mouse A. flavicollis (DOBV-Af) is responsible for clinically severe HFRS cases with 
a case fatality rate of up to 12 % [Avsic-Zupanc, 92b; Avsic-Zupanc, 95a; Papa, 
01]. Recently, DOBV-Af-like strains (Saaremaa and DOBV-Aa) have been found in 
the striped field mouse A. agrarius [Nemirov, 99; Sibold, 01a; Klempa, 03]. It has 
been proposed that mild clinical courses of DOBV infections in central and eastern 
Europe might be due to infections by those virus strains [Schütt, 01; Plyusnin, 01a; 
Golovljova, 02; Ulrich, 02; Klempa, 04a; Klempa, 04b]. 
The clinical features of HFRS are fever, headache, back and abdominal pain, drop 
in blood pressure, hypotension, and in severe cases haemorrhages, renal failure, 
shock and cardiovascular collapse. Some of these symptoms are thought to be 
caused by an increased capillary permeability and vascular leakage, a 
characteristic phenomenon of HFRS [Kanerva, 98b]. 
The reasons for the differences in severity of disease and case fatality rate caused 
by the different hantaviruses are not clear, but seem to be determined by virus- 
and host-specific factors. A major virulence factor is represented by the G1 
protein, as a change of HTNV virulence was accompanied by a change of one 
amino acid in the G1 protein [Isegawa, 94; Ebihara, 00]. In another study, 
indications were found that a mutation in the noncoding region of the S segment 
might be responsible for the infectivity of PUUV in bank voles and cell culture 
[Lundkvist, 97b]. On the other hand, it has been shown that the human HLA alleles 
B8, DR3 and DQ2 are associated with a more severe outcome of PUUV infection, 
whereas HLA allele B27 is associated with a milder outcome of PUUV infection in 
humans [Mustonen, 98a; Vapalahti, 01]. 
 
1.4 Treatment of hantavirus infections 
Hantaviruses can cause severe infections, which in some cases can result in a 
lethal outcome. Except for treatment with ribavirin, curing hantavirus infections is 
restricted to a treatment of the symptoms caused by the infection. Ribavirin, which 
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is used against a wide range of RNA viruses can help against hantavirus 
infections. There seems to be no benifit of a ribavirin treatment for patients 
infected with New World hantaviruses [Mertz, 04]. For Old World hantaviruses 
however, it has been shown that treatment with ribavirin decreases virus titres and 
increases surviving probabilities in suckling mice infected with HTNV [Huggins, 
86]. Ribavirin is a guanosine analogue and its incorporation into mRNA is followed 
by a stop in transcription. Recently, Severson and colleagues have found a higher 
mutation rate in the S segment mRNA in HTNV infected VeroE6 cells in the 
presence of ribavirin. They consider this "error catastrophe" as the reason for the 
antiviral property of ribavirin [Severson, 03]. In vivo there might be an additional 
antiviral effect of ribavirin as it has been shown that ribavirin alters the T cell 
balance to the T helper 1 (Th1) subset in hepatitis B virus (HBV)- and hepatitis C 
virus (HCV)-specific immune response [Hultgren, 98]. If this alteration in T cell 
balance maybe relevant for ribavirin treatment of hantavirus infections remains to 
be elucidated. 
 
1.5 Vaccine development 
1.5.1 Whole virus vaccines 
Because of the therapeutical limitations of infections, a prophylactic vaccine for 
hantavirus infections is needed. Several killed whole virus vaccines generated in 
mouse brains or cell culture are commercially produced and licensed for human 
use in Asia [reviewed by Krüger, 01]. HantavaxTM is a formalin-inactivated HTNV 
vaccine grown in suckling mouse brains and supplemented with alum gel as 
adjuvant [Lee, 99]. HantavaxTM seems to be efficient in preventing HFRS: In 
Korea, the number of hospitalised HFRS cases have dropped by half since 
HantavaxTM became available, from 1234 cases in 1991 to 687 cases in 1996. In 
Yugoslavia 2000 people became vaccinated with placebo or HantavaxTM. In the 
placebo group five cases of HFRS occurred while in the HantavaxTM group no 
cases of HFRS occurred [both trials reviewed in Lee, 99]. In Asia bivalent 
HTNV/SEOV vaccines have been developed [Krüger, 01; reviewed by Hooper, 
01d]. However, the whole virus vaccines are not licensed outside Asia. There are 
certain disadvantages of whole virus vaccines. (i) handling of the hantaviruses 
requires level three safety facilities which complicates the production of a vaccine. 
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(ii) Inactivation of the virus used for the vaccine could be inefficient which makes it 
obligatory to test each vaccine lot for infectivity. The need for biosafety level 
precautions and the danger due to ineffective inactivation can be circumvented by 
producing a subunit vaccine by recombinant technology.  
 
1.5.2 Recombinant proteins as potential hantavirus vaccines 
As has been outlined above, a recombinant subunit vaccine against hantaviruses 
is needed. Even though many antiviral subunit vaccines in clinical trial, so far there 
are only two on the market. One is the recombinant HBV surface antigen (HBsAg) 
expressed in yeast [McAleer, 92]. The fact that HBs particles can protect against 
HBV has been found out by immunisations with non-recombinant HBs particles 
purified from hyperimmune serum. The other is a non-recombinant influenza 
subunit vaccine [FluadTM, Chiron, Minutello, 99]. 
Previously, hantavirus vaccine candidates have been generated on the basis of 
recombinant technologies, e.g. naked DNA vaccines, recombinant vaccinia and 
related poxviruses, and recombinant proteins expressed in transgenic plants, E. 
coli, yeast and insect or mammalian cells. Taken together, several of these 
recombinant vaccines based on N or the glycoproteins are able to induce 
protective immune responses in rodent animal models [Krüger, 01; for reviews see 
Hooper, 01e].  
 
1.5.3 Recombinant virus-like particles 
Non-infectious virus-like particles (VLPs) can be generated by heterologous 
expression of viral structural proteins and their spontaneous self-assembly. A 
variety of viral proteins have been used for the development of VLPs [for review 
see Pumpen, 03]. Bacteriophage coat proteins have been found to have a very 
limited insertion capacity for foreign protein segments [Pushko, 93; Voronkova, 
02]. In contrast, bluetongue virus NS1 tubules, parvovirus B19 and yeast 
retrotransposon Ty-derived VLPs have been found to tolerate extended insertions 
of up to 100 - 200 foreign aa [Miyanohara, 86; Adams, 87; Mikhailov, 96].  
The surface and the core antigen of the HBV have been used since the 1970s as 
carrier proteins for the generation of chimeric VLPs. The core protein of HBV 
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(HBc) expressed in bacteria forms shells resembling those in HBV-infected liver 
cells [Cohen, 82]. Due to its advantageous features HBc has been extensively 
exploited as a carrier for foreign epitopes [for reviews see Ulrich, 98b; Pumpens, 
01]. Indeed, on the basis of HBV core (HBc), highly promising vaccine candidates 
have been generated for influenza [Neirynck, 99] and malaria [Sällberg, 02].  
In vaccine development, HBc provides several advantages as a carrier for foreign 
epitopes: (i) The carboxy-terminal region of HBc responsible for nucleic acid 
binding can be deleted without disturbing the formation of HBc particles [Borisova, 
89; Gallina, 89]. Particles formed by carboxy-terminally truncated HBc protein 
contain only traces of RNA [Birnbaum, 90; Ulrich, 93]. (ii) The structure of HBc 
particles has been resolved by cryoelectron microscopy and X-ray crystallography. 
In line with epitope mapping data the major immunodominant region (MIR) has 
been identified as the surface-exposed tip of spikes on the surface of HBc particles 
[Salfeld, 89; Böttcher, 97; Wynne, 99]. (iii) The MIR has been shown to be 
dispensable for particle assembly [Schödel, 92]. (iv) As expected for a highly 
repetitive antigen, HBc particles are highly immunogenic and improve the 
immunogenicity of per se low immunogenic foreign peptides presented on their 
surface [Clarke, 87; Francis, 90]. (v) In comparison to other VLP carriers, HBc has 
a favourable property in terms of vaccine development; it is not only a T cell 
dependent but also T cell independent antigen [Milich, 86b]. This T cell 
independence can be transferred to foreign segments presented on HBc particles 
[Fehr, 98].  
In previous experiments, three potential insertion sites for foreign protein segments 
into HBc have been used: the amino-terminus, the MIR and different carboxy-
terminal positions [for reviews see Ulrich, 98b; Pumpens, 01]. According to the 
three-dimensional structure [Böttcher, 97; Wynne, 99], epitope mapping data 
[Salfeld, 89] and empirical insertion data, the MIR represents the most preferential 
insertion site for foreign sequences [Schödel, 92; Borisova, 96; Lachmann, 99]. 
Therefore the MIR of the HBc protein has been chosen in this study as the place to 
insert parts of the DOBV N protein (see chapter 1.8). 
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1.5.4 The need of adjuvants in subunit vaccines 
One of the problems of generating a protein subunit vaccine, e.g. based on VLPs 
is that proteins by themselves have a rather low immunogenicity. Therefore, 
adjuvants are needed to supplement the proteins to induce a strong protein-
specific immune response. Adjuvants can either enhance or modify the immune 
response. Alternatively, they can also act as a depot so that the protein is released 
over a long period of time and thereby continuously stimulating a protein-specific 
immune response. Until recently only alum (aluminium hydroxide or aluminium 
phosphate) has been used as an adjuvant in vaccines for human use. In the year 
2000 an influenza vaccine (FluadTM, Chiron) was introduced to the market in which 
MF59, a water in oil emulsion, is used as adjuvant [Podda, 01]. The development 
of new adjuvants helping in inducing a strong protective immune response is a 
crucial step in vaccine development. Ongoing studies investigate other adjuvants 
containing saponins, or small unmethylated DNA oligonucleotides, (CpG 
dinucleotides) to be used in human vaccines. Another approach is to use 
recombinant cytokines as adjuvants in subunit vaccines.  
Complete Freund's adjuvant (CFA) due to its high content of mycobacterial cell 
wall components is a useful adjuvant in research only, but will not be certified for 
human use. But it represents a useful adjuvant to investigate if a protein is able to 
induce an immune response in animal models. In this study recombinant proteins 
were applied with CFA and incomplete Freund's adjuvant (IFA) to enable 
comparisons to the results of protection studies in an animal model [Lundkvist, 96; 
Dargeviciute, 02; de Carvalho Nicacio, 02]. 
 
1.5.5 Hantavirus proteins suitable as a subunit vaccine 
An efficient hantavirus vaccine should protect against infections by all members of 
the genus Hantavirus. To develop a broadly protective vaccine against 
hantaviruses two alternative approaches could be followed: (i) generation of a bi- 
or multivalent vaccine consisting of antigens from different hantavirus species or 
(ii) identification of antigen(s)/epitope(s) providing cross-protection against a broad 
range of different hantaviruses.  
So far, nothing is known about the potential of the RdRp as a vaccine. In the same 
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line, research about RdRp is rather limited and until recently it had not been 
heterologously expressed as an entire protein [Jonsson, 01]. In a recent study a 
part of a recombinant RdRp expressed in E. coli has been shown to be 
immunogenic in rabbits [Kukkonen, 04]. Compared to the other proteins, the RdRp 
of different hantaviruses have the highest aa identity; there is a minimum of 70 % 
aa identity between the RdRp of the hantaviruses [Tab. 2 and Kanerva, 98a]. 
Therefore, one can expect a high cross-reactivity of the immune response induced 
by RdRp. This cross-reactivity would be highly favourable for vaccine 
development. However, further investigations are needed to characterise the 
potential of RdRp as a vaccine.  
TABLE 2: Amino-acid identities (in %) in the glycoprotein precursor protein and the RNA-
dependent RNA polymerase of different hantaviruses after alignment by Clustal Method.  
HTNV ANDV SNV
Slovenia Slovakia 76-118 Vranica Sotkamo Kazan AH1 3H226
Slovenia
Slovakia 65 48 48 50
HTNV 76-118 49 49 49
Vranica 55 58
Sotkamo 69
Kazan
ANDV AH1 68 77 64
SNV 3H226 69 78 87
glycoprotein precursor 
DOBV PUUV
R
dR
p
DOBV
PUUV
Glycoprotein precursor sequences: DOBV-Slovakia (Genbank accession number AY168578), 
HTNV 76-118 (M14627), PUUV-Vranica/Hällnäs (U14136), ANDV (AF324901), SNV (L37903). 
RNA-dependent RNA polymerase (RdRp) sequences: HTNV 76-118 (D25531), PUUV-Sotkamo 
(Z66548), ANDV (AF291704), SNV (L37902). Grey areas: no sequence data available for the 
glycoprotein precursor or the polymerase of the respective hantavirus. 
 
In contrast to the RdRp, the glycoproteins are well known to have a potential as a 
vaccine. The proteins G1 and G2 can be expressed in baby hamster kidney (BHK) 
cells with the help of a alphavirus replicon [Kallio-Kokko, 01b] or by vaccinia virus 
(VACV) vectored expression [Schmaljohn, 90e]. Passive transfer of serum from 
SEOV infected rats protected rats from a subsequent SEOV challenge [Zhang, 
89]. As the serum had high neutralising antibody titres, protectivity was thought to 
be mediated by G1/G2-specific antibodies. The specificity of the transfered 
antibodies, however, was not determined. Immunisation with a VACV vector 
expressing G1 and G2, as well as passive transfer of G1/G2-specific monoclonal 
antibodies protected hamsters [Schmaljohn, 90d] and suckling mice [Arikawa, 92] 
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from a HTNV challenge. 
The glycoprotein precursors of different hantaviruses have the lowest aa identity 
among the hantavirus proteins. There is an aa identity of 50 % to 70 % of the 
glycoprotein precursors [Tab. 2 and Kanerva, 98d]. Due to these large aa 
differences in the glycoproteins of different hantavirus strains it is improbable that 
a subunit vaccine based on the glycoprotein of one hantavirus strain will protect 
against heterologous hantaviruses [Schmaljohn, 90c; Ruo, 91]. In line, serum from 
SEOV infected rats protects newborn rats against SEOV but not HTNV [Zhang, 
89]. As a neutralisation titre of 1:640 against SEOV was found in the passively 
transferred sera, protection was thought to be provided by G1/2 specific 
antibodies. Thus, G1/G2 specific antibodies might not be very cross-protective.  
It is thought that the G1/G2-specific immune response protecting against 
hantaviruses is based primarily on antibodies. However, the role of G1/G2-specific 
cellular immune response in protection against hantavirus infection has not been 
investigated so far. 
TABLE 3: Amino acid (aa) identities (in %) of the entire nucleocapsid proteins and their 
amino terminal 120 aa of different hantavirus strains used in this study. The aa identities were 
determined by alignment using the Clustal method.  
HTNV ANDV SNV
Slovenia Slovakia Fojnica Vranica Sotkamo Kazan AH1 3H226
Slovenia 98 83 60 61 60 64 62
Slovakia 98 83 60 61 60 63 61
HTNV Fojnica 84 84 60 61 61 65 62
Vranica 51 51 52 96 96 73 69
Sotkamo 50 50 51 96 97 72 70
Kazan 52 52 53 96 98 73 71
ANDV AH1 60 60 59 73 73 74 86
SNV 3H226 55 55 55 71 72 72 90
N protein, aa 1-428 (ANDV, SNV), 1-429 (DOBV, HTNV) , 1-433 (PUUV)
DOBV PUUV
N
 p
ro
te
in
, a
a 
1 
- 1
20 DOBV
PUUV
 
Sequences: DOBV-Slovenia, DOBV-Slovakia, HTNV 76-118, PUUV-Vranica/Hällnäs, PUUV-
Sotkamo, PUUV-Kazan [For all sequences see Razanskiene, 04];  ANDV-AH1 [Lopez, 97a] and 
SNV-3H226 [Hjelle, 94b]. 
 
As the N proteins of different hantaviruses are more closely related to each other 
than the glycoproteins [Tab. 2 and 3, and see Kanerva, 98c] it has since long been 
speculated that a vaccine based on N protein might be more cross-protective than 
a vaccine based on G1 and G2 [Asada, 89]. The N protein of hantaviruses is 
highly immunogenic. Natural hantavirus infections of rodents and humans result in 
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the induction of strong N-specific antibody and T cell responses [reviewed in 
Khaiboullina, 02]. In addition, immunisation of rodents with recombinant N (rN) 
protein induced N-specific B and T cell responses [Lundkvist, 97c; Ulrich, 98a; de 
Carvalho Nicacio, 01f; Dargeviciute, 02; de Carvalho Nicacio, 02]. In rodent animal 
models a protective immune response has been mediated by immunisation with 
vaccinia-vectored N-encoding vaccines [Schmaljohn, 90b; Xu, 92], E. coli-
expressed chimeric HBc particles carrying amino-terminal parts of N protein 
[Ulrich, 98a] as well as with rN proteins expressed in E. coli [Lundkvist, 96; de 
Carvalho Nicacio, 02], yeast Saccharomyces cerevisiae [Dargeviciute, 02] or 
insect cells [Schmaljohn, 90a; Lundkvist, 96; Schmaljohn, 99]. However, in a 
hamster challenge model the protection mediated by a SEOV N-encoding DNA 
vaccine was found to be low [Kamrud, 99]. 
 
1.6 Animal models for hantavirus research 
As described above, in nature hantaviruses can persistently infect their natural 
host without showing signs of disease. Although groups have tried to infect various 
rodents with hantaviruses [Asada, 88a], there are only a few natural hantavirus 
rodent hosts that have been bred in captivity to investigate hantavirus infection and 
challenge. Bank voles can be infected experimentally with PUUV [Lundkvist, 96], 
rats with HTNV [Lee, 81] and deer mice with SNV [Botten, 00]. Moreover, PUUV 
and HTNV as well as SEOV can infect Syrian hamsters [Chu, 95; Hooper, 99; 
Hooper, 01a]. Additionally to hamsters, HTNV can infect Mongolian gerbils 
(Meriones unguiculatus) in the laboratory [Xu, 92]. However, the New World 
hantaviruses ANDV and Maporal virus are the only ones that cause a lethal 
infection resembling HCPS in Syrian hamsters [Hooper, 01b; Milazzo, 02a]. 
PUUV, which readily infects its natural host, the bank vole C. glareolus could not 
infect adult immunocompetent laboratory mice like BALB/c mice [Klingström, 02a]. 
Comparably, BALB/c and ICR have been reported to be susceptible to only 
transient infection with HTNV, with virus titres in the infected mice lasting for a 
maximum of five days [Asada, 87d] or ten days [Kariwa, 95] post infection. In 
contrast to the only transient infection of laboratory mice, it has recently been 
described that immunocompetent adult BALB/c, C57BL/6 and SJL/J mice were 
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susceptible to HTNV [Wichmann, 02a]. C57BL/6 and BALB/c mice have even 
been reported to die eight to eleven days post infection [Wichmann, 02b]. These 
experiments were conducted with the same HTNV strain (76-118) used in studies 
where the virus could only transiently infect laboratory mice (see above). Thus the 
peculiarities of the HTNV used by Wichmann et al. have to be determined. DOBV 
infection experiments with BALB/c and NMRI mice resulted in almost all mice in 
the induction of DOBV N-specific antibodies. However, only some animals had S 
segment RNA and none of them had N-antigen in their lungs [Klingström, 02b]. 
Similar findings were obtained recently for DOBV infection of C57BL/6 mice, where 
infected mice developed G1/2-specific antibody response but N antigen and S 
segment RNA could not be detected in the lung [Klingström, 04]. Hence, additional 
investigations are needed to prove if DOBV can reproducibly infect laboratory 
mouse strains and if infection is transient or long lasting. 
Athymic nude mice, which have only very limited amounts of T cells, died from an 
HTNV infection [Asada, 87c]. In the same line, SCID mice which lack the 
recombinant VDJ region, leading into T cell and B cell deficiencies, died from 
HTNV and SEOV infections [Yoshimatsu, 97]. Besides the adult rodent models, 
intracerebral or subcutaneous injection with HTNV [Nakamura, 85b; Yoshimatsu, 
93] and injection with DOBV [Klingström, 03] has been shown to be lethal for 
suckling mice. 
Besides rodents, nonhuman primates can be experimentally infected with 
hantaviruses. PUUV and ANDV can both infect cynomolgous macaques leading to 
symptoms similar to those seen in human HFRS and HCPS patients, respectively 
[McElroy, 02; Klingström, 02c] . 
 
1.7 Nucleocapsid protein specific immune response 
1.7.1 Antibody response  
The N protein is the major antigenic target in the early IgG response of NE patients 
[Lundkvist, 93b] whereby after disease, more and more G1/2-specific antibodies 
can be found [Lundkvist, 93b; Vapalahti, 95a]. N-specific antibodies were present 
already at the onset of disease, while G1/2-specific IgG antibodies were present in 
only 2 % of the acute sera compared to 87 % of old immune sera from NE patients 
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[Kallio-Kokko, 01a]. Human sera contained IgG1 and IgG3 in acute sera and IgG1 
and IgG4 in the sera 2 years after infection against all three structural proteins N, 
G1 and G2 [Lundkvist, 93a].  
In rodents, the N-specific antibody response has been extensively studied, both 
after hantavirus infection as well as after immunisation with N protein constructs. 
Experimental PUUV infection as well as immunisation with PUUV rN protein 
induced a strong N-specific antibody response in bank voles [Lundkvist, 96; 
Dargeviciute, 02; de Carvalho Nicacio, 02] and laboratory mice [de Carvalho 
Nicacio, 01e]. 
The immunodominant B cell epitope region has been located at the amino 
terminus of the N protein. Human IgG response in sera of HFRS and HCPS 
patients was mostly directed to the 119 amino terminal amino acids of hantavirus 
rN protein [Jenison, 94a; Lundkvist, 95; Vapalahti, 95b; Elgh, 96a; Gött, 97; 
Milazzo, 02b]. In sera from rodent, like PUUV infected bank voles as well as most 
monoclonal antibodies derived from PUUV infected animals reacted mostly with 
amino-terminal peptides of the N protein  [Lundkvist, 96; Lundkvist, 02]. Sera of 
deer mice infected with SNV also reacted more strongly to the N-terminal aa 17-58 
compared to the remaining portion of the protein [Yamada, 95]. 
There are several indications that N-specific antibodies may play a role in 
protecting against hantavirus infection. N-specific antibodies have been 
demonstrated to provide protection against a hantavirus infection in cell culture, in 
the suckling mouse model as well as in adult bank voles [Yoshimatsu, 93; 
Yoshimatsu, 96e; Lundkvist, 02]. The immunological mechanisms behind the 
protectivity induced by N-specific antibodies remains to be clarified. Antibody-
dependent cytotoxicity (ADCC) has been discussed as one of the mechanisms by 
which the antibodies can confer protection by binding to infected cells and marking 
them for destruction [de Carvalho Nicacio, 01d]. An inhibition of transcription has 
been discussed as another mechanism by which N-specific antibodies can confer 
protection by binding to N protein, which is bound to the viral RNA and which 
subsequently inhibits transcription [Yoshimatsu, 96d]. 
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1.7.2 Cellular immune response 
In patients infected with HTNV and PUUV, the CD8+ cellular immune response 
was found to be at least partly directed against the N protein [Van Epps, 99; Van 
Epps, 02a; Terajima, 02a]. In PUUV infected NE patients G1/2-specific CD8+ cells 
have been detected [Terajima, 02b]. PUUV induced CD8+ memory cells in NE 
patients [Van Epps, 02b]. Moreover a milder NE course could be connected to 
HLA B27 [Mustonen, 98a]. Thus, cellular immune responses are likely beneficial to 
humans in terms of recovering from hantavirus disease. 
There is an ongoing controversy if the cellular immune response measured in 
acutely ill patients is connected to immunopathogenesis or protective immune 
response. It has been suggested that the N-specific CD4+ and CD8+ cells from 
SNV infected patients might be involved in immunopathogenesis [Ennis, 97]. In 
line with these findings, numerous cells producing cytokines as IL-1, IL-6, TNF-α, 
IFN-γ, IL-2, IL-4, and TNF-β were detected by immunohistochemical staining in 
autopsy tissues from HCPS patients [Morii, 99]. In another study the ratio of 
activated to non-activated lymphocytes was higher in acute HFRS patients than in 
convalescent patients [Huang, 94]. Whether these cytokine producing cells or the 
activated lymphocytes helped clearing the virus infection or were involved in 
immunopathology has yet to be elucidated.  
Hantavirus specific T cell responses have been investigated in various rodent 
studies. Cytotoxic splenocytes from HTNV infected mice have been found to lyse 
HTNV and SEOV infected macrophages [Asada, 88b]. In another study, BALB/c 
mice infected with HTNV developed IFN-γ secreting CD8+ cells as well as HTNV-
specific cytotoxic T cells (CTLs) [Araki, 03]. HTNV-specific CD4+ and CD8+ cells 
induced in mice after HTNV infection can protect mice against a HTNV challenge 
as shown in adoptive transfer experiments [Asada, 87b]. Most important in 
protection were CD5+ positive lymphocytes (T cells and subsets of B cells) as 
protection dropped most when these cells were lysed before transferring spleen 
cells from HTNV immunised mice into naive mice. As in the investigations outlined 
above, it remains to be investigated to which of the hantaviral proteins the 
protective immune response was directed against.  
For the first time cytotoxic T cells with a proven N-specificity have been generated 
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in C57BL/6 mice by infecting them with HTNV or immunising them with HTNV N 
protein-derived peptides [Park, 00]. In other studies, PUUV N-specific proliferation 
was found in splenocytes of PUUV rN protein immunised BALB/c [de Carvalho 
Nicacio, 01c] as well as of bank voles immunised with rN proteins of DOBV, ANDV 
or TOPV [de Carvalho Nicacio, 02]. 
Taken together, it is not clear what kind of N-specific immune response is needed 
to protect against hantaviruses, but it can be deduced from the studies mentioned 
above, that N-specific antibodies as well as T cells can play a role in protecting 
against a hantavirus infection. 
 
1.8 Objectives of the study 
DOBV carried by the yellow necked field mouse A. flavicollis is a highly virulent 
virus responsible for clinically severe HFRS cases with a high case fatality rate [up 
to 12 %, Avsic-Zupanc, 99] and able to kill suckling mice [Klingström, 03]. The 
main objective of this study was to compare the immunogenicity of entire rN 
protein of DOBV (strain Slovenia) to the immunogenicity of HBc particles 
harbouring 120 amino-terminal aa of DOBV (strain Slovenia) N protein 
(HBcdDOB120). To allow comparison to earlier studies, the immunisation scheme 
used in this study has previously been used in challenge experiments [Lundkvist, 
96]. 
As humoral, as well as cellular immune responses can be involved in protection 
against hantaviruses, these investigations included the characterisation of humoral 
and cellular immunity after immunisation with DOBV rN or HBcdDOB120 protein. 
The characterisation of humoral immunity should be obtained by analysis of the 
antibodies against homologous DOBV rN protein and heterologous rN proteins. 
The estimation of N-specific IgG subclasses should allow a first idea about the 
cytokine milieu created by lymphocytes involved in the N-specific immune 
response. In addition, the proliferation of N-specific lymphocytes and their secreted 
cytokines were analysed to characterise the N-specific T cell response after 
immunisation with the two proteins. 
A potential problem for the use of chimeric VLPs based on HBc might be a pre-
existing immunity due to HBV infection. Therefore, an additional aim of the study 
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was to investigate whether a pre-existing anti-HBV core immunity influences the 
subsequent immune response against a foreign protein sequence presented on 
HBc particles in mice. 
 
2 Material and methods 
2.1 Protein derivatives for immunisation 
2.1.1 Expression and purification of VLPs  
The generation of the expression plasmids for the carboxy-terminally deleted HBc 
protein (aa 1-144, HBcd) and chimeric HBc protein carrying 120 aa of the N 
protein of the hantavirus DOBV at aa 78 of HBcd (HBcdDOB120) have been 
described previously [Borisova, 88; Geldmacher, 04k]. 
Purified HBcd and HBcdDOB120 were kindly provided by Dr. Galina Borisova 
(Biomedical Research and Study Centre, Riga, Latvia). The expression in E. coli 
and purification of the HBcd particles have been described previously 
[Geldmacher, 04j]. Briefly, cells of E. coli strain K802 were transformed with 
plasmids encoding the respective core proteins. After sedimentation the cells were 
lysed and soluble proteins extracted. Core proteins were precipitated and loaded 
onto a saccharose gradient or a sepharose CL4B column. Fractions containing the 
core proteins were identified by SDS-PAGE and Western blot analysis (see 
chapter 2.2.1), concentrated and stored in glycerol at –20°C until further use. Prior 
to immunisation, the particles were diluted in PBS. 
The formation of particles of HBcd and HBcdDOB120 particles was kindly proven 
by negative staining electron microscopy by Dr. Hans R. Gelderblom [Robert 
Koch-Institut, Berlin, Germany, see Geldmacher, 04i]. 
2.1.2 Expression and purification of full-length rN protein 
The vectors for the yeast expression of the rN proteins of the hantaviruses DOBV, 
strains Slovenia [DOBV-Slo; Avsic-Zupanc, 95b] and Slovakia 
[DOBV/Esl/862Aa/98; DOBV-Slk; Sibold, 01b], HTNV, strain Fojnica [HTNV-Foj; 
Sibold, 99b], PUU, strains Vranica/Hällnäs [PUUV-Vra; Reip, 95], Kazan [PUUV-
Kaz; Lundkvist, 97a]) and Sotkamo [PUUV-Sot; Vapalahti, 92] have been 
generated and generously provided by Ausra Razanskiene [Dargeviciute, 02; 
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Razanskiene et al., 2004]. The yeast expression plasmids for the rN proteins of the 
New World hantaviruses ANDV, strain AH1 [Lopez, 97b] and SNV, strain 3H226 
[Hjelle, 94a] were generated and kindly provided by Jonas Schmidt (Schmidt et al., 
submitted). 
The expression and purification of the rN proteins was performed according to 
protocols previously described [Dargeviciute, 02; Razanskiene et al., 2004]. 
Briefly, pFX7-derived expression plasmids encoding a fusion of an amino-terminal 
hexahistidine (His)-tag and the hantavirus N proteins under the control of a 
galactose inducible yeast promoter were transformed into the yeast S. cerevisiae 
wild-type strain FH4C. The synthesis of rN proteins was induced by addition of 
galactose and proteins were purified under denaturing conditions via their His-tag 
according to the protocol of the manufacturer (Qiagen). Proteins were 
characterised in SDS polyacrylamid gel and Western blot (chapter 2.2.1). Hamster 
polyomavirus (HaPyV) VP1 protein expressed in yeast, kindly provided by Dr. 
Alma Gedvileite [see Gedvilaite, 04], served as a negative control in Western Blot. 
For immunisations DOBV rN protein was dialysed against phosphate buffered 
saline (PBS) and subsequently lyophilised. 
2.2 Characterisation of the recombinant protein derivatives  
2.2.1 SDS-PAGE and Western Blot 
Protein samples were separated by electrophoresis in 12.5 or 15 % SDS 
polyacrylamide gels. Protein bands were stained by Coomassie blue. For Western 
blot, proteins were transferred to cellulose nitrate membrane by semi-dry blotting. 
After transfer, cellulose membranes were blocked with 5 % dry milk / PBS 
containing 0.1 % Tween (PBS/T) for one hour and incubated 16 to 18 h in PBS/T 
dilutions of the mAbs 1C12, 4C3 [Lundkvist, 91; diluted 1:1,000], mouse anti-
DOBV rN serum (1:2,000 in PBS/T) or polyclonal rabbit serum raised against 
HBc/GFP particles [Kratz, 99; diluted 1:5,000 in PBS/T]. Thereafter, filters were 
incubated with the respective horse radish peroxidase (HRP)-conjugated anti-
mouse IgG (1:3000, Sigma-Aldrich) or anti-rabbit IgG (1:6,000, Sigma-Aldrich) in 
PBS/T for 2 hours. The peroxidase staining was performed by adding 4-chloro-1-
naphthol (Sigma-Aldrich) supplemented with H2O2. 
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2.2.2 Determination of protein concentration 
To determine the concentration of purified proteins, protein samples were mixed 
with Bradford reagent (0.01 % Coomassie brilliant blue G250, 8.5 % phosphoric 
acid, 5 % ethanol). After 10 to 30 min the OD595nm values were measured. To 
estimate the protein concentration, a standard curve with two-fold dilutions of 
bovine serum albumin (BSA, Sigma-Aldrich) in PBS ranging from 16 - 250 μg/ml 
was generated. In addition, the estimated protein concentrations of the different rN 
proteins were compared to each other in SDS polyacrylamid gel by Coomassie 
blue staining and adjusted accordingly. 
2.3 Immunisation of mice  
2.3.1 Mice strains 
To analyse the immunogenicity of HBcdDOB120 and DOBV rN protein inbred mice 
strains of two different haplotypes, H-2d (BALB/c) and H2-b (C57BL/6), were used 
for analysis. Groups of five female mice each were immunised at sex to ten weeks 
of age. All mice were obtained from the "Bundesinstitut für gesundheitlichen 
Verbraucherschutz und Veterinärmedizin" in Berlin and held in the Max-Planck-
Institute for Infectious Biology, Berlin. Permission of all animal experiments were 
obtained from the "Landesamt für Arbeitsschutz, Gesundheitsschutz und 
technische Sicherheit" in accordance to the German laws (§ 8 Abs. 1 des 
Tierschutzgesetzes). 
2.3.2 Immunisation of mice to investigate the influence of HBc-specific 
preexisting immunity  
The effect of a preexisting immunity against the carrier protein HBc on the 
development of anti-N antibodies after immunisation with HBcdDOB120 should be 
addressed. Thus BALB/c and C57BL/6 mice were immunised according to two 
different protocols, a “short-term” (scheme 1, Fig. 2A) and “long-term“ (scheme 2, 
Fig. 2A) protocol. In general, mice were first immunised with HBc and then, after 
animals had developed an antibody titre against HBc as evidenced by ELISA (see 
chapter 2.4.1), mice were immunised with HBcdDOB120. 
In the first set of immunisations, four BALB/c and four C57BL/6 mice per group 
were immunised subcutaneously (sc) three times with 20 µg each of full length 
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HBc in complete Freund's adjuvants (CFA, Sigma-Aldrich), incomplete Freund's 
adjuvants (IFA, Sigma-Aldrich) and without adjuvants. Six weeks after the last 
immunisation the mice had developed a high antibody titre against HBc as 
evidenced by ELISA (see chapter 2.4.1). In the "short term" experiment the 
immunisation with HBcdDOB120 (20 μg in CFA) was performed six weeks after 
the last immunisation with HBc (scheme 1, Fig. 2A). In the "long term" 
experiments, the immunisation with HBcdDOB120 (20 μg in CFA) was given five 
months after the last immunisation with HBc (scheme 2, Fig. 2A). Blood was 
collected three weeks after the final immunisation. 
immunisations:
scheme 1
50µg
+CFA
50µg50µg
+IFA
week   0                 3                6            8       35 
scheme 2
scheme 3
20µg
+CFA
20µg20µg
+IFA
week   0                        4                        8     12         14              17
20µg
+CFA
HBc HBcdDOB120
20µg
+CFA
20µg20µg
+IFA
week   0                        4                        8     37           40
20µg
+CFA
HBc HBcdDOB120
2µg
A       pre-existing immunity
B      immunogenicity of HBcdDOB120 and DOBV rN
proliferation
+
cytokines  
FIGURE 2: Immunisation schemes for BALB/c and C57BL/6 mice. To address the question 
of the influence of HBc-specific immunity to the response to the DOBV rN protein, mice were 
immunised with HBc and subsequently with HBcdDOB120 (A, schemes 1 and 2). Immunisations of 
mice with HBcdDOB120 and DOBV rN protein were done to compare the immune responses of 
mice after immunisation with the two proteins in antibody response and cellular response (B, 
scheme 3). Immunisation scheme 3 has previously been used in a hantavirus challenge model in 
bank voles (Lundkvist et al 1996). Solid arrows illustrate the time points of immunisations, while 
open arrows show the time points of bleeding of the animals. The grey arrow indicate the time point 
where animals were sacrificed an proliferation and cytokine assays performed after immunisation 
with a sub-immunogenic dose (2 μg) of DOBV rN protein. For details of the immunisations see text 
(scheme 1 and 2, chapter 2.3.2; scheme 3, chapter 2.3.3) . 
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2.3.3 Immunisation of mice with HBcdDOB120 and DOBV rN protein  
To investigate the immunogenicity of HBcdDOB120 and DOBV rN protein, groups 
of five BALB/c and five C57BL/6 mice were immunised according to a scheme 
which was previously used in a PUUV challenge model [Lundkvist, 96]. Briefly, 
mice were immunised sc three times with 50 µg of HBcdDOB120 or DOBV-Slo rN 
protein at intervals of three weeks (scheme 3, Fig. 2B). Mice were immunised with 
the proteins in PBS with CFA, IFA and without adjuvant, respectively. For negative 
control, mice were immunised three times with HBcd or PBS in the same 
adjuvants, respectively. 
To assess the N-specific cellular immune response, BALB/c and C57BL/6 mice 
used for the characterisation of the antibody response were injected with 2 µg of 
DOBV rN protein seven to eight months after the last immunisation with 
HBcdDOB120 or DOBV rN protein, respectively (scheme 3, Fig 2B). Four days 
after immunisation, mice were sacrificed and single cell suspensions were 
prepared from a pool of inguinal, axial and brachial lymph nodes (see chapter 
2.4.3). 
 
2.3.4 Bleeding and storage of blood 
Blood was collected by bleeding of the tail vein. After the blood clotting it was 
centrifuged and sera were aliquoted and stored at –20 °C. Once sera were thawed 
for use in ELISA, they were subsequently stored at 4 °C. 
 
2.4 Characterisation of the immune response of mice  
2.4.1 ELISA  
Elisa was performed as described previously [Geldmacher, 04a]. Briefly, rN 
proteins [10 µg/ml] in coating buffer (40 mM Na2CO3, 60 mM NaHCO3, pH 9.8) 
were coated onto Maxisorb Plates (Nunc) overnight at 4°C. Coated plates were 
blocked with 150 µl / well of blockingbuffer (1 % BSA, 0.01 % Tween-20, PBS) for 
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30 min at 37 °C. The sera were then diluted in 100 μl / well at a minimum dilution 
of 1:50 in ELISA-buffer (0.5 % BSA, 0.01 % Tween-20, PBS), titrated three-fold 
and incubated for 1 h at 37°C. Specific antibody binding was detected by 
incubation with HRP-labelled rabbit anti-mouse-IgG in ELISA-buffer (1:8,000, 
Sigma-Aldrich) for 1 h at 37°C. Assays were developed with o-phenylenediamine 
(Sigma-Aldrich) in 0.05 M phospho-citrate buffer (Sigma-Aldrich) supplemented 
with 1.5 o/oo H2O2 and stopped with 50 µl 0.6 M H2SO4 after 20 min at room 
temperature. The optical density (OD) was read at 492 nm with a reference 
wavelength of 620 nm. 
The titres of antibodies of the different IgG subclasses were determined similarly to 
total IgG as follows. Coating, blocking and serum dilution were done as described 
above for the IgG ELISA. After incubation of sera, goat anti-IgG1, anti-IgG2a, anti-
IgG2b and anti-IgG3 antibodies (1:1,000, Sigma-Aldrich) were added to the plates 
for one hour. Finally, binding of anti-IgG subclass antibodies was detected by 
HRP-labelled anti-goat IgG and immuno-staining as described above. 
The endpoint titre was defined as the serum dilution where the OD is three times 
the background OD. The background OD is the OD that is measured in highly 
diluted sera and does not decrease with further dilution. In our experiments the 
background OD varied between 0.02 and 0.1. The OD due to unspecific binding 
was subtracted from each OD of the respective serum dilution. Unspecific binding 
is the binding to N of antibodies in the negative control sera of the respective 
dilution. 
To rule out that the IgG subclass titres differed due to a difference in affinity of IgG 
subclass specific antibodies, ELISAs with coating of plates with threefold dilutions 
of recombinant IgG1, IgG2a, IgG2b and IgG3 were performed (Sigma Aldrich), 
starting with concentrations of 100 – 300 ng/ml. After blocking, the adding of anti-
IgG1, -IgG2a, -IgG2b or -IgG3 was done according to the IgG subclass ELISA 
described above. It turned out that the anti-IgG1 antibody gave a three times lower 
OD as the anti-IgG subclass antibody that gave the highest OD (anti-IgG3) at the 
same IgG-subclass concentration. Thus the mistake in the IgG subclass 
distribution in the mouse sera due to the difference in affinity of the anti-IgG 
subclass antibodies used in the ELISA is maximal three fold and – as log scale is 
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used in the figure – does not have a big impact on the ELISA results. 
 
2.4.2 Immunofluorecence assay (IFA)  
VeroE6 cells infected with DOBV (strain Slovenia), HTNV (strain 76-118) or PUUV 
(strain Sotkamo) were seeded in 8 – 12-well coverslips and grown overnight. The 
next day, cells were washed with PBS, fixed with acetone/methanol (1:2) and a 
1:1,000, 1:5,000 or 1:10,000 dilution of serum pools of mice immunised three 
times with HBcdDOB120 or DOBV rN protein (scheme 3, Fig. 2) in PBS/10% 
rabbit serum was added. For visualisation, rabbit anti–mouse IgG fluorescein 
isothiocyanate (FITC)-conjugated secondary antibody was used. 
 
2.4.3 Preparation of single cell suspensions from lymph nodes  
.For the investigation of the lymphocyte proliferation, inguinal, axial and brachial 
lymph nodes of single mice were pooled and mashed through a 70 µm cell strainer 
(FALCON). Cells were pelleted by centrifugation (530 x g, 5 min, 4 °C) and taken 
up in RPMI medium (Biochrome), 5 % heat-inactivated foetal calf serum (FCS, 
Biochrome), 2 mM L-glutamine, 100U/ml penicillin, 100 µg/ml streptomycin, 50 µM 
2-mercaptoethanol and 25 mM HEPES. The concentration of living cells was 
determined by trypan blue dye staining. A minimum of 100 live cells were counted 
with a Bürker chamber and cells were adjusted to the concentration needed (see 
chapter 2.4.4). 
 
2.4.4 Proliferation and cytokine assays for the determination of N-specific 
lymphocytes 
To analyse the proliferation of N-specific lymphocytes, lymph node cells of mice 
immunised with HBcdDOB120 or DOBV rN proteins (scheme 3, Fig 2B) were 
restimulated in vitro with DOBV rN protein. Doublets of 600,000 cells were seeded 
in 200 µl medium / well of a 96-well round bottom plate. Cells were restimulated at 
37 °C, 5 % CO2 for 3 days with concentrations of 0, 0.03, 0.16, 0.80, 4.00 and 
20.00 µg/ml DOBV-Slo rN protein. As a positive control cells were treated with 4 
µg/ml concanavalin A (Con A, Sigma-Aldrich). In addition, cells from animals 
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immunised with DOBV rN protein were restimulated with rG2 to assess the impact 
that the His tag or potential yeast contamination might have on the proliferation.  
After 24 hours of restimulation 30 µl per well supernatant was removed for IL-2 
testing and BrdU was added to the cells according to the BrdU proliferation test 
protocol (Roche). After 48 hours of restimulation 50 µl per well supernatant was 
removed for the IL-4 and IFN-γ testing and 44,000 of the 600,000 cells per well 
were transferred to a flat-bottom microtitre plate. After centrifugation (530 x g, 5 
min, 4 °C) of the plate the medium was removed. The rest of the cells were 
restored in the incubator. After another 72 hours, 44,000 cells were removed for 
the proliferation test and the supernatant was saved for IL-4 and IFN-γ tests The 
BrdU ELISA was performed according to the BrdU Proliferation ELISA protocol 
(Roche). The stimulation indices (SI) was calculated as the ratio of the OD value 
obtained by the respective antigen concentration to the OD value obtained by 
medium only.  
As outlined above supernatants were collected from lymph node cells after 24 h 
restimulation for IL-2 testing and after 48 h and 72 h restimulation for IL-4 and IFN-
γ testing. IL-2, IL-4 and IFN-γ was quantified in the supernatant according to the 
manufacturers protocols (R&D) for a sandwich ELISA. Detection limits of the tests 
were between 7 and 30 pg/ml. 
 
2.5 Data analysis 
Antibody endpoint titres of each mouse as determined by ELISA was transformed 
to 10log and average and standard deviation determined for each immunisation 
group (HBcdDOB120 and DOBV rN protein). By means of the proliferation assay, 
average SI values (see 2.4.4) and standard deviations were determined for each 
mouse and each restimulation antigen concentration from duplets. This average SI 
was then averaged again to calculate the average of each of the immunisation 
groups for each restimulating antigen concentration. Similarily, cytokine 
concentrations in the supernatant were determined for each mouse and each 
restimulating antigen concentration and averages and standard deviations were 
calculated for each immunisation group. All data analysis were done for BALB/c 
and C57BL/6 mice separately. Where appropriate, data were analysed for 
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significant differences using a Mann-Whittney U Test (see respective results 
paragraphs).  
 
3 Results 
3.1 HBcdDOB120 and DOBV rN were expressed in E. coli and S. 
cerevisiae, respectively 
HBcdDOB120 can be expressed in E. coli and purified according to protocols 
described previously [Borisova, 88; Geldmacher, 04h]. The HBcdDOB120 protein 
is pure as proven by Coomassie blue staining (Fig. 3A), and was recognised by 
HBc-specific as well as N-specific antibodies in Western Blot (Fig. 4A,B).  
The HBcd protein is only recognised by the HBc-specific antibodies. The purified 
HBcd and HBcdDOB120 proteins self-assembles into particles, as shown by 
electron microscopy [data not shown, see Geldmacher, 04g]. The 120 amino-
terminal aa is at least partly exposed on the outside of the particles, as shown by 
immuno electron microscopy [data not shown, see Geldmacher, 04f].  
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FIGURE 3 Coomassie blue stained SDS polyacrylamid gels of the antigens HBcdDOB120 
(A) and rN protein of Dobrava virus (DOBV) strain Slovenia (Slo) (B) used in the 
immunisation experiments. In addition to the proteins used for immunisations the following were 
analysed: HBcd, which was used as a negative control in the immunisations with HBcdDOB120 
(A), as well as the proteins that were used for the detection of cross-reactive antibodies against the 
N protein of the following hantaviruses: DOBV strain Slovakia (Slk), Hantaan (HTNV) strain Fojnica 
(Foj), Puumala (PUUV) strains Vranica/Hällnäs (Vra), Kazan (Kaz) and Sotkamo (Sot), Andes 
(ANDV) strain AH1 and Sin Nombre (SNV) strain 3H226. 
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The entire rN proteins of DOBV-Slo, DOBV-Slk, HTNV-Foj, PUUV-Vra, PUUV-Sot, 
PUUV-Kaz, AND-AH1 and SNV-3H226 could be expressed to high level in the 
yeast S. cerevisiae. They were purified by nickel chelate affinity chromatography 
by means of the His-tag as proven by Coomassie blue staining of SDS 
polyacrylamid gel (Fig. 3B). All the proteins, but not the negative control, the 
hamster polyomavirus (HaPyV) VP1 protein were recognised by an N-specific 
mAb (Fig. 4C). 
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FIGURE 4 Western Blot analysis of the antigens HBcdDOB120 (A, B) and rN protein of 
Dobrava virus (DOBV) strain Slovenia (Slo) (C) used in the immunisation experiments. 
Detection of proteins were conducted using polyclonal HBc-specific serum (A), polyclonal 
hantavirus N-specific serum (B) or the N-specific mAb 1C12 (C). Additionally to the immunising 
antigens HBcd (A, B) is shown, which was used as a negative control in the immunisations with 
HBcdDOB120, as well as the proteins that were used for the detection of cross-reactive antibodies 
against the N protein (C) of the following hantaviruses: DOBV strain Slovakia (Slk), Hantaan 
(HTNV) strain Fojnica (Foj), Puumala (PUUV) strains Vranica/Hällnäs (Vra), Kazan (Kaz) and 
Sotkamo (Sot), Andes (ANDV) strain AH1 and Sin Nombre (SNV) strain 3H26.  
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3.2 Preexisiting antibodies to HBc did not abrogate the antibody 
response to DOBV rN protein after immunisation with HBcdDOB120 
To investigate if an earlier acquired immune response to the carrier protein HBc 
influences the N-specific immune response after subsequent HBcdDOB120 
immunisation, mice with a high HBc-specific antibody titre were immunised with 
HBcdDOB120 six weeks after the last HBc immunisation (scheme 1, Fig. 2A). For 
comparison naive mice were immunised with HBcdDOB120 according to the same 
scheme.  
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FIGURE 5: DOBV N-specific antibody response in BALB/c (above) and C57BL/6 (below) 
mice with HBc-specific immunity and naive mice after immunisation with HBcdDOB120. In a 
first set of immunisations groups of four BALB/c and four C57BL/6 mice were immunised with full-
length HBc  which resulted in a HBc-specific antibody titre of at least 1:100,000 one months after 
HBc vaccination (scheme 1, Fig. 2A) or 1:1,000 seven month after HBc vaccination (scheme 2, Fig. 
2A). In a second set of immunisation a group of these mice as well as a group of naive mice were 
immunised once with HBcdDOB120 in complete Freund's adjuvant. Groups of mice were 
immunised with HBcdDOB120 either 1.5 months (A) (scheme 1, Fig. 2A) or seven months (B) 
(scheme 2, Fig. 2A) after the last immunisation with HBc. Shown are the means of the reciprocal 
DOBV rN-specific endpoint titres of four mice with the respective standard deviation. The mean titre 
of the mice immunised according to the seven months scheme (B) is based on only three mice. 
Titres did not exhibit significant differences when tested by Mann Whittney U Test (p>0.05). 
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BALB/c and C57BL/6 mice with a mean HBc-specific antibody titre of 1:250,000 
had the same DOBV N-specific antibody titre after immunisation with 
HBcdDOB120 as mice not possessing an HBc-specific antibody titre before 
HBcdDOB120 immunisation (Fig. 5A). The preexisiting HBc-specific as well as the 
induced N-specific antibodies were of all IgG subclasses (data not shown). 
Similarly, BALB/c mice pre-immunised with carboxy-terminally truncated HBcd 
developed higher DOBV N-specific titres after HBcdDOB120 immunisation than 
mice that were not preimmunised with HBcd (data not shown, Geldmacher et al. 
unpublished data). 
In another experiment groups of mice immunised with HBc were left for seven 
months before immunising them with HBcdDOB120 (scheme 2, Fig. 2A), to see if 
a presumable memory immune response to HBc would influence the immune 
response to DOBV rN protein.  
BALB/c and C57BL/6 mice with an HBc-specific antibody titre of 1:1,000 seven 
months after the HBc immunisation developed a one order of magnitude higher 
DOBV N-specific antibody titre after immunisation with HBcdDOB120 compared to 
mice that did not have any HBc-specific antibody titre before HBcdDOB120 
immunisation (Fig. 5B). However, the DOBV N-specific antibody titres of mice with 
and without a preexisting HBcd-specific titre were not significantly different from 
each other (p>0.05). As observed for the sera of mice immunised according to the 
"short term" scheme (scheme 1, Fig. 2), HBc-specific and N-specific antibodies 
were of all IgG subclasses (data not shown). 
 
 
3.3 HBcdDOB120 and DOBV rN induced antibodies that reacted to virus 
infected cells 
Serum pools of mice immunised with HBcdDOB120 particles or DOBV rN protein 
were tested for their reactivity with the natively folded N protein in hantavirus-
infected cells.  
A serum pool of mice immunised with HBcdDOB120 particles reacted with natively 
  36
folded N protein in DOBV infected cells, but not with uninfected VeroE6 cells (Fig. 
6). In addition, the serum pool also reacted with HTNV and PUUV infected cells 
(data not shown). Sera of mice immunised with HBcd did not react with DOBV 
infected cells (data not shown).  
A serum pool of mice immunised with DOBV rN also reacted with DOBV infected 
cells, but not with uninfected VeroE6 cells (Fig. 6). The pool of control sera of mice 
immunised with PBS did not react with DOBV infected cells (data not shown). 
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FIGURE 6: Reactivity of serum pools from mice immunised with HBcdDOB120 and DOBV 
rN protein with DOBV infected VeroE6 cells. Sera from five BALB/c mice taken three weeks 
after the third immunisation (scheme 3, Fig. 2B) were pooled and diluted 1:1,000. Shown is the 
immunofluorescence of DOBV infected and non-infected cells incubated with serum pools induced 
by immunisations with HBcdDOB120 and DOBV rN protein detected by a FITC-conjugated anti-
mouse antibody at a 40-fold magnification.  
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3.4 HBcdDOB120 and DOBV rN induced a strong and long lasting 
antibody response  
To compare the immunogenicity of HBcdDOB120 and DOBV rN protein by 
immunising BALB/c and C57BL/6 mice three times with HBcdDOB120 or DOBV rN 
protein (scheme 3, Fig. 2B). Individual sera taken after each immunisation were 
tested in ELISA with the homologous rN protein (DOBV-Slo).  
Immunisation of BALB/c and C57BL/6 mice with DOBV rN protein resulted in  high 
titres of homologous N-specific antibody titres. The first immunisation induced N-
specific antibody titres of 1:8,000 in BALB/c (Fig. 7A) and 1:60,000 in C57BL/6 
(Fig. 7B). In BALB/c mice this titre was significantly higher than in mice immunised 
with HBcdDOB120 (p = 0.032).  
BALB/c and C57BL/6 mice immunised with chimeric HBcdDOB120 particles both 
developed high antibody titres against DOBV rN protein. Three weeks after the 
first immunisation N-specific antibody titres were as high as 1:20,000 in BALB/c 
(Fig. 7A) and 1:200,000 in C57BL/6 mice (Fig. 7B). The antibody titre had its peak 
after the third immunisation with titres of 1:650,000 and 1:250,000, respectively. 
Eight months after the last immunisation, antibody titres had dropped to 1:55,000 
in BALB/c (Fig. 7A) and 1:50,000 in C57BL/6 mice (Fig. 7B). No DOBV rN-specific 
antibodies were found in the serum pool of control mice immunised with HBcd 
(data not shown). 
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  FIGURE 7: Kinetics of DOBV N-specific antibody response. BALB/c (A) and C57BL/6 (B) mice 
were immunised according to scheme 3 (Fig. 2B) three times with 50 µg of HBcdDOB120 or DOBV 
rN protein in complete Freund's adjuvant (week 0), incomplete Freund's adjuvant (week 3) or 
without adjuvant (week 6), respectively. N-specific antibody endpoint titres (three times the 
background) were determined in ELISA for each mouse separately. Shown are the means of 
reciprocal endpoint titres of 5 mice and the respective standard deviations. Stars indicate significant 
differences in log10 titres between mice immunised with HBcdDOB120 compared to mice 
immunised with DOBV rN protein as determined by Mann Whittney U Test (p < 0.05). 
 
Like in HBcdDOB120 immunised mice the highest antibody titre was found after 
the third immunisation with titres of 1:800,000 and 1:1,000,000, respectively. At this 
time point significantly higher titres were found in mice immunised with DOBV rN 
protein compared to HBcdDOB120. Eight months after the last DOBV rN protein 
immunisation, antibody titres had dropped to 1:150,000 in BALB/c (Fig. 7A) and 
1:100,000 in C57BL/6 mice (Fig. 7B). Serum pools from sera of animals 
immunised with DOBV-Slo rN protein did not develop any titre against yeast-
expressed DOBV-Slo G2, used as a negative control (data not shown). In addition, 
no DOBV rN-specific antibodies were found in the serum pool of control mice 
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immunised with PBS (data not shown). 
 
3.5 HBcdDOB120 and DOBV rN protein induced antibodies are highly 
cross-reactive to the rN proteins of other hantaviruses  
The reactivity of sera from mice immunised three times with HBcdDOB120 or 
DOBV-Slo rN protein to the rN proteins of other hantaviruses was analysed. 
Therefore, individual sera taken two weeks after the final immunisation with 
HBcdDOB120 or DOBV rN protein (both based on the N protein of DOBV-Slo) 
were tested for antibodies reacting with the rN proteins of DOBV-Slk, HTNV-Foj, 
PUUV-Vra, PUUV-Kaz and PUUV-Sot, SNV-3H226 and ANDV-AH1. 
Sera of mice immunised with HBcdDOB120 were all reactive to the rN proteins of 
DOBV-Slk, HTNV-Foj and PUUV-Vra, PUUV-Kaz, and PUUV-Sot, ANDV-AH1 and 
SNV-3H226 when tested in ELISA (Fig. 8A,B). The pattern of cross-reactivity did 
not differ between BALB/c and C57BL/6 mice. The cross-reactivity was highest to 
the heterologous rN proteins of the more closely related HTNV. However, 
reactivities were significantly lower to the more distantly related PUUV-Kaz (only in 
BALB/c mice, p=0.032) and PUUV-Vra (p=0.008 BALB/c; p=0.016 C57BL/6). 
Reactivities to PUUV-Sot, SNV and ANDV were not found to be significantly 
different to the reactivity to DOBV (Fig. 8A,B).  
In immunofluorescence assay, a highly diluted (1:10,000) serum pool from 
HBcdDOB120 vaccinated BALB/c mice showed highest fluorescence intensity and 
more cells immunofluorescence positive on HTNV infected cells. Sera showed 
similar intensity on DOBV infected VeroE6 cells but much lower intensity of 
fluorescence and fewer immunofluorescence positive PUUV infected cells (data 
not shown). Interestingly, the level of cross-reactivity was lower when a serum pool 
was tested in Western Blot. Serum of mice immunised with HBcdDOB120 reacted 
to a low extent to the rN proteins of PUUV-Kaz and PUUV-Sot and did not react at 
all to rN protein of PUUV-Vra (data not shown). However, both tests are not 
quantitative as the intensity of immunofluorescence and the intensity of the bands 
in Western Blot could only be estimated. 
 
  40
0
1
2
3
4
5
6
7
Slo Slk Foj Kaz Vra Sot 3H226 AH1
R
ec
ip
ro
ca
l e
nd
po
in
t t
ite
r  [
lo
g 
]
1
0
BALB/c
C57BL/6
DOBV HTNV PUUV SNV ANDV
0
1
2
3
4
5
6
7
Slo Slk Foj Kaz Vra Sot 3H226 AH1
HBcdDOB120 DOBV rN
Antibodies specific for rN protein of 
A
B
** **
** ** *
 
FIGURE 8: Analysis of the cross-reactivity of antibodies of BALB/c (A) and C57BL/6 (B) mice 
two weeks after the third immunisation with 50 µg HBcdDOB120 or DOBV rN protein 
(scheme 3, Fig. 2B). Antibodies induced by either of those two constructs based on the rN protein 
of hantavirus strain Dobrava Slovenia (DOBV-Slo) were tested on the reactivity with the rN proteins 
of the hantaviruses DOBV strain Slovakia (Slk), Hantaan virus (HTNV) strain Fojnica (Foj), 
Puumala viruses (PUUV) strains Kazan (Kaz), Vranica/Hällnäs (Vra), Sotkamo (Sot), Sin Nombre 
virus (SNV) strain 3H226 and Andes virus (ANDV) strain AH1. Endpoint titres (three times the 
background) of each animal was determined by ELISA. Shown are the arithmetic mean values and 
standard deviations of the reciprocal endpoint titres of five animals. Stars indicate significant 
differences in log10 titres between DOBV-Slo-specific titres compared to antibody titres reacting to 
the N protein of other hantaviruses as determined by Mann Whittney U Test (p < 0.05). 
 
In general, the sera of mice immunised with DOBV-Slo rN protein reacted in ELISA 
strongly with all rN proteins (Fig. 8A,B). The pattern of cross-reactivity did not differ 
between BALB/c (Fig. 8A) and C57BL/6 (Fig. 8B) mice. The reactivity of the sera 
from both BALB/c and C57BL/6 mice immunised with DOBV-Slo rN protein to the 
rN protein of the more closely related DOBV-Slk and HTNV-Foj was slightly 
stronger when compared with the reactivity to the rN proteins of the PUUV strains 
(Fig. 8A,B). In both mouse strains, the reactivity was significantly lower to PUUV-
Vra (p=0.008), PUUV-Sot (p=0.008 BALB/c; p=0.032 C57BL/6). Only sera from 
C57BL/6, but not BALB/c mice immunised with DOBV rN reacted to significantly 
lower level to ANDV-AH1 rN protein (p=0.032). 
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In immunofluorescence assay highly diluted (1:10,000) pool of sera from DOBV rN 
protein immunised BALB/c mice reacted strongly to HTNV and DOBV infected 
VeroE6 cells but weaker to PUUV infected cells (data not shown). In Western Blot, 
the serum pool of mice immunised with DOBV-Slo rN protein reacted with the rN 
proteins of both DOBV, HTN and all three PUUV strains (data not shown). 
 
3.6 HBcdDOB120 and DOBV rN induced N-specific antibodies of all IgG 
subclasses  
To get a first idea which kind of immune response is induced by HBcdDOB120 
particles and DOBV rN protein in mice, we determined titres of N-specific 
antibodies of the IgG subclasses IgG1, IgG2a, IgG2b and IgG3. In addition, titre 
ratios of IgG1/IgG2a as well as titre ratios of all four IgG subclasses to total IgG 
were calculated to characterise the (mostly T cell secreted) cytokine environment 
when B cells were activated.  
HBcdDOB120 induced in BALB/c and C57BL/6 mice N-specific antibodies of all 
IgG subclasses, IgG1, IgG2a, IgG2b and IgG3 to a similar extend (Figs 9A,B). The 
ratio of IgG1/IgG2a was between 1.0 and 1.2 in BALB/c and between 1.1 and 1.5 
in C57BL/6 mice at four time points after the first immunisation (Tab. 4).  
Besides IgG1 and IgG2a antibodies, IgG2b and IgG3 were measured in the sera 
of mice immunised with HBcdDOB120. In the sera taken the mean IgG2b/IgG 
ratios lay between 0.70 and 1.02 while the IgG3/IgG ratios were between 0.67 and 
0.82 (Tab. 4). 
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FIGURE 9: IgG subclass distribution of DOBV N-specific antibodies in sera of mice two 
weeks after the last of three immunisations with HBcdDOB120 or DOBV rN protein. Shown 
are the arithmetic means and standard deviations of the reciprocal endpoint titres (three times the 
background) of five animals. Each titre was determined separately by ELISA for each animal. 
Comparability of the anti-IgG1, anti-IgG2a, anti-IgG2b and anti-IgG3 antibodies used in the ELISA 
was confirmed in a special ELISA (see chapter 2.4.1).  
 
In mice sera after immunisation with DOBV rN protein N-specific IgG of all 
subclasses were found to be induced (Figs 9C,D). However, we observed a slight 
dominance of IgG1 over IgG2a, IgG2b and IgG3 in the sera of BALB/c mice (Fig. 
9C). This dominance of IgG1 over the other IgG subclasses was detected in sera 
after each immunisation step (Tab. 4). In the sera of C57BL/6 mice IgG1 
dominated over IgG2b, followed by IgG2a and IgG3 (Fig. 9D). As observed in 
BALB/c mice, this dominance could be seen in sera of C57BL/6 mice after each 
immunisation (Tab. 4). 
In sera taken at four time points the mean IgG2b/IgG ratios laid between 0.48 and 
0.61 for BALB/c and 0.84 and 0.93 for C57BL/6 without showing a time-dependent 
pattern (Tab. 4). The IgG3/IgG ratios were between 0.65 and 0.73, decreasing with 
time after immunisation (Tab. 4). 
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TABLE 4: Ratios of N-specific antibody titre of IgG subclasses to total IgG and IgG1 to 
IgG2a ratios at various time points after immunisation of BALB/c and C57BL/6 mice with 
HBcdDOB120 particles or DOBV rN protein. Animals were immunised three times (weeks 0, 3 
and 6) with 50 μg in adjuvants according to scheme 3 (Fig. 2B) and bled at various time points. 
Shown are the means (in bold) and the standard deviation (s) of five animals of the ratios of 
antibody titres that as determined by ELISA.  
time 
pointa  
mouse 
strain 
immunisation 
antigen 
IgG1/IgGb 
meand    s 
IgG2a/IgGb 
meand   s 
IgG2b/IgGb 
meand   s 
IgG3/IgGb 
meand   s 
IgG1/IgG2ac
meand    s 
3 
6 
8 
35 
HBcdDOB120 0.97 
0.98 
0.82 
0.90 
0.11 
0.08 
0.06 
0.07 
0.81 
0.90 
0.82 
0.84 
0.09 
0.07 
0.06 
0.07 
0.86 
0.83 
0.72 
0.70 
0.11 
0.08 
0.08 
0.07 
0.81 
0.81 
0.74 
0.72 
0.10 
0.03 
0.05 
0.04 
1.20 
1.10 
1.01 
1.08 
0.12 
0.15 
0.13 
0.15 
3 
6 
8 
35 
BALB/c 
DOBV rN 1.08 
0.95 
1.02 
1.04 
0.07 
0.04 
0.03 
0.08 
0.68 
0.73 
0.77 
0.81 
0.05 
0.05 
0.03 
0.05 
0.60 
0.50 
0.48 
0.60 
0.05 
0.10 
0.13 
0.11 
0.73 
0.70 
0.72 
0.70 
0.05 
0.04 
0.04 
0.02 
1.58 
1.30 
1.31 
1.28 
0.09 
0.08 
0.00 
0.06 
3 
6 
8 
35 
HBcdDOB120 0.93 
0.92 
0.89 
0.77 
0.04 
0.10 
0.03 
0.08 
0.64 
0.68 
0.79 
0.57 
0.08 
0.03 
0.04 
0.02 
0.93 
0.90 
1.02 
0.98 
0.07 
0.06 
0.07 
0.04 
0.82 
0.79 
0.73 
0.67 
0.01 
0.04 
0.07 
0.05 
1.47 
1.35 
1.14 
1.36 
0.17 
0.16 
0.05 
0.13 
3 
6 
8 
35 
C57BL/6 
DOBV rN 1.00 
0.98 
0.99 
0.87 
0.07 
0.03 
0.03 
0.04 
0.64 
0.67 
0.69 
0.59 
0.04 
0.03 
0.05 
0.04 
0.92 
0.93 
0.92 
0.84 
0.04 
0.03 
0.00 
0.09 
0.72 
0.72 
0.67 
0.65 
0.03 
0.03 
0.04 
0.04 
1.58 
1.47 
1.44 
1.48 
0.13 
0.08 
0.13 
0.04 
a weeks after first immunisation 
b ratios of the N-specific log10 reciprocal antibody titre of IgG subclass to IgG total  
c ratios of the N-specific log10 reciprocal antibody titre of IgG1 to IgG2a 
d The HBcdDOB120 induced ratios that significantly differ from DOBV rN induced ratios are in italic 
  and underlined (p<0.05). Analysis of significant differences by Mann-Whittney U Test, done 
  separately for BALB/c and C57BL/6 mice. 
 
3.7 Proliferation of N-specific lymphocytes was low after immunisation 
with HBcdDOB120 or DOBV rN protein 
To investigate the cellular immune response, mice immunised three times with 
HBcdDOB120 or DOBV rN protein were subsequently immunised with a low dose 
of DOBV rN protein in order to bring the N-specific lymphocytes back to the 
draining lymph nodes.  
Mice previously immunised with HBcd and PBS, respectively, were also 
immunised with the same dose of DOBV rN to guarantee the "sub-immunogenic" 
nature of this low dose. Proliferation of cells was determined using  6x105 
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(BALB/c) or 4x105 (C57BL/6) cells per per well. 
In mice immunised with HBcdDOB120 only small (BALB/c) or no (C57BL/6) 
proliferative response after restimulation with DOBV rN could be detected (Fig. 
10). The highest proliferative response, a stimulation index (SI) of 2.2 developed 
after a restimulation with 4 µg/ml DOBV rN protein. These results are 
representative for three other experiments conducted on cells from BALB/c mice 
treated the same way as in the experiment shown here (data not shown). 
Restimulation of cells with 4 µg/ml ConA resulted in strong proliferation with SIs of 
4 to 14 (BALB/c) or 40 (C57/BL6) (data not shown). 
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FIGURE 10: Analysis of N-specific proliferation of lymph node cells. One Mouse was 
immunised three times sc with HBcdDOB120 or DOBV rN protein (scheme 3, Fig 2B). Seven 
months after the last immunisation these mice were injected with a sub-immunogenic dose of 2 µg 
DOBV rN protein to induce the N-specific lymphocytes to home to the draining lymph nodes. 
Control mice previously immunised with HBcd or PBS were immunised the same way. Four days 
after the injection of the sub-immunogenic dose doublets of 6 x 105 (BALB/c) or 4 x 105 (C57BL/6) 
cells from the pooled inguinal, axial and brachial lymph nodes were restimulated for 72 h in vitro 
with different concentrations of DOBV rN protein or left untreated in complete RPMI medium. In 
addition, cells from animals immunised with DOBV-Slo rN were restimulated with rG2 protein to 
assess if the His tag or potential yeast contaminations have an impact on the proliferation. Level of 
proliferation was determined by means of brom-desoxyuridine incorporation (Roche). The 
stimulation index was calculated as the proliferation induced by the respective antigen 
concentration divided by the proliferation induced by medium alone. Shown are means of doublets 
with the respective standard deviations.  
  45
Immunisation of mice with DOBV rN protein resulted in proliferative responses in 
BALB/c and C57BL/6 mice after restimulation with DOBV rN protein (Fig. 10). The 
strongest N-specific responses, with SIs of over 5 (BALB/c) and over 3 (C57BL/6), 
were found after restimulation with 4 µg/ml and 20 µg/ml DOBV rN protein.  
In BALB/c mice restimulation with His-tagged rG2 protein purified in a similar way 
as DOBV rN protein also induced cells that were immunised with DOBV rN protein 
to proliferate (Fig. 10). The proliferation of cells from BALB/c mice immunised with 
DOBV rN protein caused by rG2 protein was variable and in some antigen 
concentrations higher than the proliferation caused by DOBV rN protein (Fig. 10). 
The same was seen in the other three experiments (data not shown).  
In contrast, lymph node cells of C57BL/6 mice immunised with DOBV rN protein 
did not proliferate at all when restimulated with rG2 protein. The same was the 
case for the lymph node cells from C57BL/6 and BALB/c mice immunised with 
PBS after restimulation with DOBV rN protein or rG2 protein (Fig. 10 and data not 
shown). Cells from mice immunised with HBcdDOB120 did also not proliferate 
after restimulation with 20 μg/ml rG2 protein (data not shown). Restimulation of 
cells with 4 µg/ml Con A resulted in strong proliferation (see 3.4.1.1). 
 
3.8 Higher cytokine levels were secreted after immunisation with DOBV 
rN protein than after immunisation with HBcdDOB120 
Cytokines IL-2, IL-4 and IFN-γ were measured in the supernatant of mouse cells 
used in the proliferation assay (see above). As in the proliferation assay, cytokine 
concentrations in the supernatant of BALB/c cells were not comparable to the 
cytokine concentrations in the supernatant of C57BL/6 cells because less cells of 
the latter per well were cultured (see above). 
The cells of BALB/c mice (Figs 11, 13) and a C57BL/6 (Fig. 12) mouse immunised 
with HBcdDOB120 secreted only very little amounts of IL-2 after restimulation with 
DOBV rN protein. The highest levels of IL-2, 80 pg/ml in BALB/c (Fig. 11) and 7 
pg/ml in C57BL/6 (Fig. 12) cell supernatants, were detected after restimulation with 
20 µg/ml DOBV rN protein. 
Cells of mice immunised with HBcdDOB120 secreted very little (BALB/c) or no 
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(C57BL/6) IL-4 and IFN-γ after restimulation with DOBV rN protein. Like IL-2, 
BALB/c cells secreted the highest amount of IFN-γ (230 pg/ml) after restimulation 
with 20 µg/ml DOBV rN (Fig. 11) At this concentration lymphocytes secreted the 
most IL-4 and IFN-γ after 48 h (Fig. 13) and 72 h (Fig. 11) of restimulation. 
However, in one experiment highest IL-4 concentrations (80 pg/ml) were found 
after restimulation of lymphocytes with 5 μg/ml DOBV rN (data not shown).  
Lymphocytes from control mice immunised with HBcd secreted also low amounts 
of cytokines after restimulation with DOBV rN protein (Figs 11-13). Highest 
concentrations of IL-4 (< 70 pg/ml) and IFN-γ (< 90 pg/ml) were emitted by BALB/c 
lymphocytes after restimulation with DOBV rN protein for 72 h (Figs 11).  
The cells from BALB/c mice (Fig. 11, 13) and a C57BL/6 mouse (Fig. 12) 
immunised with DOBV rN protein both secreted IL-2 after restimulation with DOBV 
rN protein. However, level of IL-2 was much higher in the supernatant of BALB/c 
lymphocytes compared to the supernatant of C57BL/6 lymphocytes. The highest 
level of secretion was observed after restimulation with 20 µg/ml, 1,500 pg/ml in 
BALB/c cells  and 75 pg/ml in C57BL/6 cells. Restimulation of the lymph node cells 
from BALB/c, but not the C57BL/6 mouse with rG2 control protein resulted in the 
detection of IL-2 secretion of more than half of the level after restimulation with rN 
protein (Figs 11, 12). 
Immunisation of BALB/c and C57BL/6 mice with DOBV rN protein induced lymph 
node cells to secrete high amounts of IL-4 and IFN-γ after restimulation with DOBV 
rN protein (Figs 11-13). Highest secretion of IL-4 was 930 pg/ml (BALB/c, Fig. 11) 
and 540 pg/ml (C57BL/6, Fig. 12) after restimulation of cells with 20 µg/ml DOBV 
rN protein. Also IFN-γ was secreted most after restimulation of cells with 20 µg/ml, 
4,800 pg/ml in BALB/c (Fig. 11) and 1,400 pg/ml in C57BL/6 cells (Fig. 12). In the 
same line, BALB/c lymphocytes secreted the highest amounts of IL-4 and IFN-γ 
after 48 h of restimulation with 20 μg/ml rN protein (Figs 13). 
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FIGURE 11: Analysis of IL-2, IL-4 and IFN-γ secreted by lymphocytes from four BALB/c 
mice. Mice were immunised with HBcdDOB120 or DOBV rN protein and supernatant from cultured 
lymphocytes was collected after 24h (IL-2) or 72 h (IL-4, IFN-γ) of restimulation with different 
concentrations of DOBV rN protein. Negative control mice were immunised with HBcd and PBS, 
respectively. Cells from mice immunised with DOBV rN protein were additionally restimulated with 
rG2 protein to estimate cytokine secretion due to cells reacting to His-tag or potential yeast 
contaminations. Supernatants were taken from cells used in the proliferation assay (Fig. 10) and 
cytokine concentrations were determined by sandwich ELISA (chapter 2.4.4). 
 
Restimulation with rG2 protein also caused the cells from BALB/c, but not cells 
from the C57BL/6 mouse immunised with DOBV rN protein to secrete high 
amounts of IL-4 and IFN-γ (Figs 11, 12). However, the level of IL-4 and IFN-γ 
induction was lower at most restimulating antigen concentration when compared to 
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rN protein stimulation (Figs 11, 12).  
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FIGURE 12: Analysis of IL-2, IL-4 and IFN-γ secreted by lymphocytes from one C57BL/6 
mouse. Mice were immunised with HBcdDOB120 or DOBV rN protein and supernatant from 
cultured lymphocytes was collected after 24h (IL-2) or 72 h (IL-4, IFN-γ) of restimulation with 
different concentrations of DOBV rN protein. Negative control mice were immunised with HBcd and 
PBS, respectively. Cells from mice immunised with DOBV rN protein were additionally restimulated 
with rG2 protein to estimate cytokine secretion due to cells reacting to His-tag or potential yeast 
contaminations. Supernatants were taken from cells used in the proliferation assay (Fig. 10) and 
cytokine concentrations were determined by sandwich ELISA (chapter 2.4.4). 
 
Cells of mice immunised with PBS did not secrete any IL-2, IL-4 or IFN-γ (Figs 11-
13). 
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FIGURE 13: Analysis of IFN-γ and IL-4 secreted by lymphocytes from four BALB/c mice. 
Mice were immunised with HBcdDOB120 or DOBV rN protein and supernatant from cultured 
lymphocytes was collected after 48 h of restimulation with different concentrations of DOBV rN 
protein. Negative control mice were immunised with HBcd and PBS, respectively. Cells from mice 
immunised with DOBV rN protein were additionally restimulated with rG2 protein to estimate 
cytokine secretion due to cells reacting to His-tag or potential yeast contaminations. Supernatants 
were taken from cells used in the proliferation assay (Fig. 10) and cytokine concentrations were 
determined by sandwich ELISA (chapter 2.4.4). 
 
 
4 Discussion  
4.1 A preexisiting immunity to the carrier protein rather boosts the 
immunity to the antigenic insert 
Hepatitis B is a widespread infection resulting in a high prevalence of anti-HBc 
antibodies in the human population worldwide. These pre-exisiting anti-HBc 
antibodies might influence the success of a vaccine based on HBc as a carrier 
protein. In this study data are presented that a preexisting immunity to HBc 
induced by immunisation with particles formed by entire core protein did not 
abrogate the DOBV N-specific antibody response after immunisation with 
HBcdDOB120. Similarly, in mice preexisting antibodies to HBV small surface 
  50
antigen (HBs) only slightly suppressed the antibody response against part of the 
hepatitis C virus envelope presented on HBs particles [Netter, 03]. In line, in mice 
immunised with a Haemophilus influenzae type B (HiB) polysaccharide/BSA 
vaccine, an enhancing effect of BSA carrier protein-specific preexisting antibodies 
on the anti-HiB immune response was observed [Schneerson, 80]. In children that 
were primed with a diphteria toxin also an enhanced immunogenicity of a HiB 
polysaccharide coupled to diphteria toxin was found [Granoff, 93].  
The antigen dose used for priming the anti-carrier immune response has been 
reported to influence the outcome whether the immune response to the respective 
antigen presented on the carrier is enhanced or suppressed [Peeters, 91]. 
Therefore, additional studies are needed to investigate if the titre of preexisting 
anti-core antibodies might influence the results of the immunisation with chimeric 
particles. Additionally it should be investigated, if the dose of HBcdDOB120 
influences DOBV N-specific titre in mice with anti-core immunity. 
These data are in contrast to the negative influence of a preexisting immunity to 
the carrier when trying to deliver a vaccinia virus construct encoding HTNV N and 
glycoproteins to vaccinia virus-immune volunteers [McClain, 00]. In the same line, 
in mice with preexisting immunity to an adenovirus (AdV) carrier, the expression of 
luciferase provided by an AdV-luciferase gene vector was significantly decreased 
compared to mice lacking an AdV-specific immunity [Vlachaki, 02]. Preexisting 
antibodies against human papillomavirus (HPV) capsid proteins L1/L2 also 
abolished the protection from a tumor challenge in mice immunised with chimeric 
HPV-L1/L2 VLPs harbouring a tumor protein segment expressed by the tumor [Da 
Silva, 01c; Da Silva, 03b]. 
Likely, the presence of carrier-specific antibodies might result in the opsonisation 
of most particles, of both viral vectors and VLPs, and their uptake by antigen 
presenting cells (APCs) via Fc receptors. Therefore, a possible explanation for the 
different influence of a preexisting immunity on DNA-based vectors versus nucleic 
acid-free VLPs might be the following. When vectors or particles are opsonised 
with antibodies, foreign protein-encoding DNA in the vector gets degraded. On the 
other hand the foreign protein insert of chimeric VLPs will gets presented better on 
MHC class I and II. This enhanced MHC class II presentation could induce a 
stronger insert-specific antibody response. As such an enhancement of peptide 
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presentation on MHC class I and II has been shown after covering protein with 
antibodies [Zheng, 01a; Zheng, 01b; Rafiq, 02a] this could be an explanation for 
the higher antibody response in mice with preexisting carrier-specific antibody titre. 
However, this does not explain the lower protectivity against tumors in mice with a 
preexisting L1/L2-specific immune response after immunisation of mice with 
chimeric L1/L2/tumor antigen particles [Da Silva, 01b; Da Silva, 03a]. It seems that 
particles that consist on carrier proteins that confer receptor dependent uptake, 
like papillomavirus L1/L2 [Da Silva, 01a] induction of insert specific immune 
response is hampered by preexisiting carrier specific immune response. This is in 
contrast to particles based on carrier proteins HBc (this study) and small HBs 
[Netter, 03]. 
Here, only the influence of a preexisting antibody response to the carrier protein on 
the insert-specific antibody response was measured. But, as preimmunisation 
induced HBc-specific IgG of all subclasses, it is likely that the preimmunisation 
also induced HBc-specific T-cells, as would happen in a natural HBV infection. 
This suggests that an immunisation with HBc-derived VLPs would be successful in 
people that once were infected with HBV. However, it remains to be proven if HBc-
specific T cells have an abolishing effect on the induction of insert-specific 
immunity or protection. Additionally it should be proven if the immune response 
obtained in mice with a preexisting anti-core immunity can be confirmed in the 
situation of a preexisting immunity due to HBV infection, e.g. in a primate model.  
 
4.2 DOBV N proteins induce a similar immune response as other 
hantavirus N proteins  
In south-east Europe the A. flavicollis-adapted DOBV is the major cause of severe 
clinical courses of HFRS. In addition, experimental inoculation of this virus was 
found to kill suckling mice [Klingström, 03]. While the immunogenicity and 
protectivity of PUUV rN protein in rodents has been investigated in several studies 
[de Carvalho Nicacio, 01b; Dargeviciute, 02; de Carvalho Nicacio, 02], less is 
known about the immunogenicity of DOBV rN protein. Therefore, in this study the 
immunogenicity of two different protein derivatives based on the N protein of an A. 
flavicollis-adapted DOBV, HBcdDOB120 and DOBV rN protein was investigated. 
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In line with initial immunisation studies in rabbits [Razanskiene, 04], high antibody 
titres were induced in BALB/c and C57BL/6 mice strains by immunisation with 
HBcdDOB120 and DOBV rN protein. This strong immunogenicity is also reflected 
by the fact, that already after the primary immunisation a high-titred antibody 
response was observed. These data are similar to those found for E. coli-
expressed PUUV-Kaz and yeast-expressed PUUV-Vra rN proteins in the same 
mice strains [de Carvalho Nicacio, 01a; A. Zvirbliene et al., unpublished data]. The 
homologous antibody titres observed by us after immunisation with DOBV rN 
protein were comparable to homologous antibody titres in bank voles after 
immunisation with PUUV-Kaz rN protein, but much higher than those found in 
bank voles after immunisation with DOBV-Slo rN protein [de Carvalho Nicacio, 02]. 
If this difference is caused by the different expression systems used to produce the 
rN proteins or by a suboptimal detection of bank vole antibodies by anti-mouse IgG 
remains to be elucidated.  
As previously observed for entire E. coli-expressed rN proteins of different 
hantaviruses (de Carvalho Nicacio et al., 2002), immunisations of mice with 
chimeric HBc particles and entire DOBV rN protein resulted in a highly cross-
reactive antibody response. As discussed below (chapter 4.4), this confirms again 
previous data about a highly cross-reactive region located in the amino-terminus of 
the N protein.  
In the same line, rabbit sera raised against yeast-expressed rN proteins of DOBV 
and HTNV [Razanskiene, 04] and sera from mice immunised with DOBV-Slo rN 
and HBcdDOB120 protein (this study) showed the same pattern of cross-reactivity. 
The sera reacted to high extent to the rN proteins of HTNV and DOBV and to 
slightly lower extent to PUUV, SNV and ANDV. The same lower reactivity to PUUV 
and ANDV rN protein was found in sera of DOBV-Slo rN protein immunised bank 
voles [de Carvalho Nicacio, 02]. For the sera of DOBV rN and HBcdDOB120 
immunised mice from this study this pattern of cross-reactivity was not only 
observed in ELISA, but also in immunofluorescence analysis using HTNV- and 
PUUV-infected Vero E6 cells. When looking at PUUV immunised rabbits 
[Razanskiene, 04] and PUUV or ANDV immunised bank voles [de Carvalho 
Nicacio, 02] the reverse cross-reactivity can be seen, with lower reactions to rN 
proteins of DOBV and HTNV.  
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Interestingly, this very high level of cross-reactivity could not be found by Western 
Blot analysis of sera from HBcdDOB120 immunised mice; the sera reacted only 
weakly with rN proteins of PUUV-Sot and PUUV-Kaz and not at all with PUUV-Vra. 
This might mean that the cross-reactive antibody bind to conformational epitopes 
that were destroyed by the reducing SDS buffer used in the gels. On the other side 
this could reflect the lower sensitivity of Western Blots compared to ELISA. Thus, 
further investigation are needed to investigate if the conformational nature of the 
epitopes of cross-reactive antibodies induced by the immunisation with 
HBcdDOB120 is responsible for the lack of reactivity to denatured PUUV rN. 
In this study N-specific IgG of all subclasses were detected in mice after 
immunisation with DOBV rN protein. In the same line, N-specific antibodies of the 
subclasses IgG1, IgG2a and IgG2b were found in BALB/c and C57BL/6 mice after 
two immunisations with PUUV rN protein, supplemented with the same adjuvants 
as used in this study [de Carvalho Nicacio, 01g]. However, in contrast to this study, 
no IgG3 was found. If this difference to the data outlined in this study is due to 
intrinsic properties of the rN proteins from different hantaviruses, due to the 
differences in expression systems, E. coli [de Carvalho Nicacio, 01h] and yeast 
(this study) or due to differences in the affinity of the detection antibody used 
remains to be investigated.  
HBcdDOB120, as DOBV rN protein also induced N-specific IgG of all four 
subclasses. In line with that, immunisation of mice with chimeric HBcdHTN120 or 
HBcdPUUV120 VLPs or chimeric HaPyV VP1-derived VLPs harbouring 120 aa of 
PUUV-Vra N protein [Gedvilaite, 04] also resulted in the induction of N-specific 
antibodies of all four IgG subclasses. The presence of all all IgG subclasses, 
especially IgG1 and IgG2a, suggests the induction of a mixed Th1/Th2 response 
(see chapter 4.5).  
In respect to cellular immune response, HBcdDOB120 (this study) induced the 
same low levels of IL-2 and IL-4 secretion as the chimeric HaPyV VP1 VLPs 
harbouring 120 aa of PUU N protein [Gedvilaite, 04]. However, immunisation of 
bank voles with E. coli-derived rN proteins of DOBV, PUUV and ANDV [de 
Carvalho Nicacio, 02] resulted in the generation of PUUV N-specific lymphocytes. 
In contrast, this study showed that immunisation of mice with yeast-derived DOBV 
rN protein resulted in low levels of DOBV N-specific lymphocytes (further 
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discussed in chapter 4.5). In the future it should be investigated what determines 
this difference in N-specific lymphocyte induction. Thus, proliferative response of 
DOBV N-specific lymphocytes of mice or bank voles immunised with E. coli-and 
yeast-derived DOBV rN protein, respectively, should be investigated in the same 
experiment.  
Taken together, besides the induction of only low levels of N-specific lymphocytes 
after DOBV rN protein found in this study, HBcdDOB120 and DOBV rN proteins 
induce a similar immune response as other recombinant hantavirus constructs. 
 
4.3 Freund's adjuvants enhances the immune response, but does not 
seem to modify the N-specific Th1/Th2 cell ratio  
The antibody titres found after immunisation with HBcdDOB120 with adjuvant 
[data presented here and Geldmacher, 04e] were half to one order of magnitude 
higher compared to antibody titres in mice immunised with HBcdDOB120 without 
adjuvants (Geldmacher et al., unpubl. data). The immunisation scheme without 
adjuvant was in dosis and time schedule the same as the immunisation scheme 
described in Geldmacher et al., 2004b. Similarly, the N-specific antibody titre after 
immunisation of mice with HaPyV VP1-derived VLPs harbouring 120 aa of the 
PUU-Vra N protein with adjuvant was about one order of magnitude higher than 
that observed by immunisation with the same particles but without adjuvant 
[Gedvilaite, 04]. 
The use of CFA and IFA as adjuvants during immunisations not only amplifies the 
immune response, but can lead to a more Th1 and more Th2 dominated immune 
response, respectively [Billiau, 01a]. Therefore the induction of a mixed Th1/Th2 
response by HBcdDOB120 and DOBV rN protein as shown in this study might be 
due to the use of adjuvants. However, immunisation of mice without adjuvants with 
chimeric HBcdDOB120, HBcdHTN120 or HBcdPUUV120 particles (Geldmacher et 
al., unpubl. data, see paragraph above) or DOBV rN protein without adjuvant 
(Niedrig and Geldmacher, unpubl. data) also resulted in the induction of all IgG 
subclassed and thereby in a mixed Th1/Th2 response. The same was found after 
immunisation of mice with chimeric HaPyV VP1-derived VLPs harbouring 120 aa 
of PUUV-Vra N protein [Gedvilaite, 04]. This suggests that the chimeric particles 
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and entire rN protein are able to mediate the induction of a mixed Th1/Th2 
response and that the induction of subclasses are not biased by the presence of 
the added adjuvant. 
Vaccination of mice with DOBV rN and HBcdDOB120 protein both resulted in the 
induction of a long-lasting N-specific immunity. Even eight months after the last 
immunisation high N-specific antibody titres in both mice strain were found, which 
suggests a possible induction of memory B cells. Alternatively, long term storage 
of rN protein in the organism, as is believed to be caused by the adjuvants CFA 
and IFA [see  Billiau, 01b], and thereby repeated activation of B cells could be 
responsible. The half life of IgG in the serum of mice is only several days [Vieira, 
86; Vieira, 88] and thereby too short to explain the presence of such high antibody 
titre in the serum months after immunisation without the presence of N-specific B 
cells.  
To study if memory B cells are induced, mice should be vaccinated with the two rN 
protein derivatives and the immune response should be characterised after several 
months, e.g. by means of a B cell ELISPOT. In the B cell ELISPOT, B cells get 
activated to secrete antigen-specific antibodies, including effector memory B cells 
as well as central memory B cells [Crotty, 04]. The same should be done for 
immunisation of mice without adjuvants. 
The data indicates that adding CFA and IFA as adjuvants in this study had 
increased the N-specific immunity but did not seem to bias the immune response 
towards Th1 or Th2. However, immunisations of DOBV rN protein without 
adjuvants was investigated in a very small number of mice (Niedrig and 
Geldmacher, unpubl. data). Thus, mice should be immunised with DOBV rN 
protein without adjuvants to test further if the same kind of immune response is 
induced as with adjuvants. Additionally, lymphocytes of these mice should be 
tested on their cytokine secretion pattern (e.g. IFN-γ versus IL5) by ELISPOT 
assay, intracellular cytokine staining or cytokine secretion assay to characterise 
the N-specific Th1/Th2 response more directly. 
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4.4 The antibody response induced by chimeric HBcd protein 
resembles the one induced by entire rN protein 
In the bank vole challenge model [Lundkvist, 96], animals have been challenged 
two weeks after the third immunisation. The antibody titres detected in the present 
study two weeks after the third immunisation with complete rN protein (429 aa) are 
slightly higher than titres found after immunisation with HBcdDOB120 particles 
carrying 120 amino acids of the rN protein. The same slightly higher antibody titre 
is seen in BALB/c mice immunised with complete rN of PUUV-Vra compared to 
titres of mice immunised with VLPs carrying 120 aa of the PUUV rN protein 
[Gedvilaite, 04, Zvirbliene unpubl. data].  
An immunisation with lower doses (10 µg, 20 µg) of HBcdDOB120 resulted in 
C57BL/6 mice in an about one fold lower reciprocal log antibody titre than BALB/c 
mice [Geldmacher, 04d, Geldmacher et al., unpubl. data and 4.3]. In contrast, the 
immunisation with a high dose (50 μg) of HBcdDOB120 induced the same N-
specific antibody titre in BALB/c and C57BL/6 mice. The lower antibody response 
in C57BL/6 mice when immunised with a low dose of particles might be explained 
by the fact that C57BL/6 mice, compared to BALB/c mice, represent weaker 
responders to the HBc antigen [Milich, 87]. However this lower response in 
C57BL/6 mice could be overcome by immunising mice with a higher dose of 
chimeric particles as shown in this study. 
The titres of N-specific antibodies in mice immunised with HBcdDOB120 particles 
were only slightly lower than those observed in mice immunised with the entire 
yeast-expressed rN protein of DOBV-Slo. On the one hand this outcome reflects 
the fact that the amino-terminus of the N protein represents the immunodominant 
region of this protein [Jenison, 94b; Lundkvist, 96; Elgh, 96b; Gött, 97]. On the 
other hand these slightly lower titres might be explained by the presence of 
additional, more carboxy-terminally located epitopes in N protein [for references 
see Lundkvist, 02]. The strong cross-reactivity of sera from mice immunised with 
HBcdDOB120 or DOBV rN protein found in this study is also confirmed by binding 
of mAbs, directed against the amino-terminal region of N, to heterologous N 
proteins [Dzagurova, 95; Yoshimatsu, 96c; Razanskiene, 04]. 
Taken together, besides the slightly lower antibody titre and the lack of cross-
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reactivity to denatured PUU-Vra rN protein in the sera of HBcdDOB120 immunised 
sera, HBcdDOB120 and DOBV rN protein induce very similar antibody response. 
 
4.5 Chimeric HBc particles as well as entire rN protein induce some N-
specific lymphocytes 
A switch in IgG subclasses indicates the presence of T helper cells (Th cells). The 
occurrence of the subclass IgG2a in mouse sera is strongly correlated to IFN-γ-
secreting Th1 cells while the presence of IgG1 is strongly correlated to IL-4-
secreting Th2 cells [Isakson, 82; Snapper, 87]. So far, a similarly strong correlation 
between the subclasses IgG2b and IgG3 to any cytokine has not been found 
[Snapper, 97]. Nevertheless, IgG subclass switching to IgG2b has been thought of 
being forced by TGF-β produced by several cell types [reviewed by Benoist, 98]. 
However, IgG2b generation is not driven by Th1 nor Th2 cells [Stevens, 88]. The 
production of IgG3 has been induced by IFN-γ in the presence of anti-IgD 
antibodies coupled to dextran and IL-5 (Snapper 1992), but inhibited by IFN-γ in 
the presence of LPS [Snapper, 87]. In addition Th1 as well as Th2 cells can induce 
an IgG subclass switch towards IgG3 [Stevens, 88]. The latter experiments 
indicated that an IgG subclass switch in B cells does not entirely depend on 
cytokine regimes.  
The majority of IFN-γ and IL-4 that induce IgG subclass switches is secreted by 
Th1 and Th2 cells, respectively. NK, NKT and mast cells also secrete IFN-γ and 
IL-4, respectively, but are present in only small amounts in the lymph nodes and 
spleen, where B cell isotype switching is thought to mainly take place. 
The N-specific IgG subclass distribution after HBcdDOB120 vaccination might 
have been induced solely by the presentation of N protein on HBcd particles and 
not by the intrinsic antigenicity of the N insert. Truncated HBcd particles have been 
proven before to induce, compared to full length HBc, a IgG1 dominated IgG 
subclass response [Milich, 97a], due to the lack of the RNA binding domain in 
truncated HBcd [Riedl, 02]. However, as complete DOBV rN is also inducing a 
similar IgG subclass distribution, the IgG subclass distribution might be caused by 
an intrinsic property of the N protein and not by HBcd carrier characteristics. 
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HBcdDOB120 VLPs and DOBV rN protein both induced N-specific IgG antibodies 
of all subclasses. The IgG1 to IgG2a ratio is slightly smaller in the serum of 
animals immunised with HBcdDOB120 compared to the ratio in sera of animals 
immunised with DOBV rN protein. As outlined above, this indicates a stronger 
influence of IFN-γ in the mice immunised with HBcdDOB120 compared to the 
influence of IFN-γ in mice immunised with DOBV rN protein. Nevertheless the ratio 
of IgG1 to IgG2a at all time points is above 1 also in HBcdDOB120 immunised 
animals suggesting dominance of IL-4 and thus Th2 cells. This bias towards Th2 is 
expected when immunising with protein, as external proteins are known to induce 
a stronger antibody and Th2 cell than CTL and Th1 cell response. However, lymph 
node cells of animals immunised with HBcdDOB120 showed very little proliferation 
and cytokines after restimulation with DOBV rN.  
T cells, secreting IFN-γ and IL-4, leading to N-specific IgG2a and IgG1 switch, 
respectively (see above) have most probably been present during B cell activation 
after HBcdDOB120 and DOBV rN protein immunisation. It is possible that HBcd-
specific T cells helped N-specific T cells in terms of proliferation by secreting IL-2. 
However, HBcd-specific T cell proliferation is low after immunisation with HBe 
[Milich, 97b], a protein very similar to the C-terminally truncated HBcd used in this 
study. However some HBc-specific T cell proliferation has been observed after 
immunising BALB/c mice with HBcd [Borisova, 93a]. Therefore, in this study the 
cytokines present at the IgG subclass switch of N-specific B cells probably could 
have come partly from N-specific and partly from HBcd-specific T cells. However, 
levels of N-specific T cells were low, as seen by the low proliferation and low 
secretion of IL-2, IL-4 and IFN-γ. 
It has been found that part of the HBV surface antigen (HBs) inserted into a C-
terminally truncated HBcd induced more insert-specific T cell proliferation 
[Borisova, 93b] compared to this study. In the same line, it has been shown that a 
papillomavirus E17 protein epitope inserted into particles composed of full length 
HBc protein can induce E17-specific T cell proliferation as well as IL-2 and IL-4 
secretion [Tindle, 94]. In both cases, the epitope was inserted at the same region 
of HBc as the 120 aa of the DOBV N protein into the C-terminally truncated HBcd 
used in this study. As has been shown previously, HBc/epitope fusion proteins 
elicited low or no epitope-specific CTL responses in mice [Street, 99; Storni, 02] 
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indicating limited induction of a Th1/CTL response. The two protein derivatives 
used in this study also did not generate any cytolytic T cells in five experiments 
(Geldmacher unpubl. data). However, those experiments should be repeated with 
a positive control group of mice immunised with an N protein construct that 
induces N-specific CTLs. This would make it possible to investigate whether the 
target cells that expressed N protein could be lysed by N-specific CTLs.  
In contrast to this study, a stronger induction of N-specific T cells was found in 
bank voles after immunisation with E. coli-derived DOBV rN protein [de Carvalho 
Nicacio, 02, see chapter 4.2]. One explanation for this difference in T cell induction 
could be the difference in time from immunisation to the sacrificing of the animals. 
When a moderately high proliferation of N-specific spleenocytes were found after 
immunisation with E. coli-derived rN proteins days after immunisation [de Carvalho 
Nicacio, 02], while a longer time schedule was used in this study (see Fig. 2B). 
However, two other experiments in which BALB/c mice were sacrificed a few days 
after HBcdDOB120 and DOBV rN protein immunisation (Geldmacher, unpubl. 
data) the same proliferation as shown in Fig. 10 was found: no or hardly any N-
specific proliferation after HBcdDOB120 and an SI of up to 5 in lymph node cells 
from DOBV rN protein immunised mice. This indicates that the difference in N-
specific proliferative response when comparing the data described by De Carvalho 
Nicacio [de Carvalho Nicacio, 02] and the data described in this study is not due to 
differences in immunisation schedule. 
Lymphocytes from mice immunised with DOBV rN proliferated after restimulation 
with DOBV rN, but proliferated in some antigen concentrations as strongly after 
restimulation with a yeast-expressed negative control protein, rG2. However, it has 
recently been found out that there is a problem with measuring the concentration 
of rG2, as it is not well coloured by Bradford reagent nor by Coomassie and 
thereby concentration is often underjudged (Razanskiene, personal 
communication). Therefore, if amounts of restimulating G2 was underestimated by 
two fold, then some N-specific T cells were induced after DOBV rN protein 
immunisation. Another proof for the induction of N-specific T cells after 
immunisation with DOBV rN protein is the high N-specific IL-2 secretion by 
lymphocytes. However, further investigations studying the induction of N-specific T 
cells are needed, e.g. by measuring proliferation using a different protein as 
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negative control.  
 
4.6 Compared to DOBV rN protein HBcdDOB120 seems to need less T 
cell help to induce an N-specific immune response. 
After the first immunisation the antibody titre in BALB/c and C57BL/6 mice 
immunised with HBcdDOB120 is slightly higher than in animals immunised with 
complete rN protein. The sligthly higher titre of animals immunised with 
HBcdDOB120 after the first immunisation could be due to the T cell independent B 
cell activation by the repetitive nature of the HBc antigen as described for nude 
B10.BR mice [Milich, 86a]. In another study, chimeric HBc particles have been 
shown to induce T cell independent insert-specific antibodies in mice [Fehr, 98]. 
When antigens, so called T cell independent antigens, do not require T cells for 
activating B cells, they are thought to induce a more rapid antibody response 
compared to T cell dependent antigens [DeFranco, 98].  
Besides the particulate nature, LPS contamination of HBcdDOB120 [Geldmacher, 
04c] is another possible cause for the more rapid antibody response induced by 
HBcdDOB120 compared to the antibody response induced by DOBV rN protein. 
LPS can also act as a T cell independent antigen and polyclonally activate B cells 
[reviewed by DeFranco, 98]. When immunising mice with HBcdDOB120 particles, 
the contaminating LPS might still be in the proximity of the particles after 
immunisation. The LPS could then activate DOBV N-specific B cells that would 
otherwise be activated much later, after N-specific T cell help became available.  
In nude mice, which lack most T cells, HBc particles are able to induce IgG 
antibodies, most of which were of the IgG2b subclass [Milich, 87]. Other studies 
showed a predominance of IgG3 in the sera of fully immunocompetent animals 
immunised with T cell independent antigens [Snapper, 87; Snapper, 92; Snapper, 
97]. When comparing the ratio of the DOBV rN-induced IgG2b and IgG3 antibody 
titre to the total IgG antibody titre a slightly higher ratio in sera of animals 
immunised with HBcdDOB120 compared to the ratio in sera of animals immunised 
with DOBV rN protein were observed. In addition to the rapid antibody response 
after immunisation with HBcdDOB120 described above, these high IgG2b and 
IgG3 titres might be further evidence for the partially T cell independent nature of 
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HBcdDOB120 particles. Additionally, the high IgG3 titre indicated that not LPS 
contamination is causing the T cell independent nature of the HBcdDOB120 
particles as the presence of IFN-γ seems to inhibit IgG3 in LPS-activated B cells 
[Snapper, 87]. However, only the ratios of IgG2b, but not IgG3 to total IgG were 
significantely higher in HBcdDOB120 immunised BALB/c (but not C57BL/6) mice 
compared to animals immunised with DOBV rN, a protein that is very probably not 
a T cell independent B cell activator.  
Additional studies are needed to tackle the question of the T cell independent 
nature of HBcdDOB120. Thus immunisations without adjuvants might elucidate if 
antibody titres in sera of HBcdDOB120 primed mice are higher than in DOBV rN 
protein primed mice. Furthermore immunisation of mostly T cell deficient nude 
mice with HBcdDOB120 particles are needed to investigate if this more rapid 
response is due to the T cell independent nature of the particles. Additionally, 
HBcdDOB120 without LPS contamination [as described in Geldmacher, 04b] and 
non-particulate HBcdDOB120 could be generated to see if the immune response 
is induced by the particulate nature of the protein or due to the T cell independent 
nature of the LPS contaminating the particles.  
 
4.7 Protection against hantaviruses can be confered by N-specific T 
cells as well as N-specific antibodies 
In 1985 it was suggested that T cell mediated immunity plays a crucial role in 
fighting hantavirus infection in laboratory rodents that - in contrast to the natural 
rodent reservoir - cannot be persistently infected [Nakamura, 85a]. The possibility 
to readily infect T cell deficient nude mice but only transiently infect 
immunocompetent BALB/c mice with HTNV [Asada, 87a] also indicated that T 
cells are important in protection against hantavirus infection. However, T cells are 
needed for an efficient B cell response. Consequently the lack of a T cell help to B 
cells might be in part responsible for the persisting infection of nude mice and for 
the failure to persistently infect immunocompetent mice with hantaviruses.  
In the same line it has been shown in adoptive transfer experiments that CD4+ and 
CD8+ cells are of importance in the protection against a HTNV challenge in mice 
[Asada, 87e]. The biggest drop in protection was observed when Lyt1+ (CD5+) 
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cells were lysed before transferring spleen cells from HTNV immunised mice to 
naive mice. As CD5 is expressed on T cells and a subset of B cells this underlines 
again the necessity for these cell types in protection against hantavirus infection. 
However, the specificity the transferred cells had not been studied. 
Splenocytes of bank voles immunised with rN proteins of different hantaviruses 
proliferated to a similar extent after restimulation with PUUV rN protein [de 
Carvalho Nicacio, 02]. However, N-specific stimulation indices were slightly higher 
after immunisation with rN protein of PUUV and Topographov (TOPV). As the rN 
protein of these two hantaviruses protected all 16 bank voles against PUUV 
infection, this suggests a role for N-specific T cells in protection [de Carvalho 
Nicacio, 02]. In contrast to N-specific splenocyte proliferation, N-specific antibody 
response was not directly associated to protection. PUUV N-specific antibody 
response was highest in PUUV rN protein, but second highest in the ANDV rN 
protein immunised group, in which only  three of eight bank voles were protected 
against a PUUV challenge [de Carvalho Nicacio, 02]. This might suggest a 
stronger importance of N-specific T cells than of N-specific antibodies in protection 
against the virus. However, the level of N-specific lymphocyte proliferation as well 
as N-specific antibody titre both did not correlate significantly with protection. 
Additionally, splenocytes of DOBV rN protein immunised bank voles proliferated to 
a similar level as cells from ANDV rN protein immunised animals, even though 
DOBV rN protein protected twice as many animals (7 of 10) as ANDV rN protein (3 
of 8) [de Carvalho Nicacio, 02]. As the titre of PUUV N-reactive antibodies was 
higher in ANDV rN protein immunised bank voles, antibody level could not explain 
this difference in protection. One explanation for the higher protection of DOBV rN 
protein immunised animals could be that DOBV rN protein harbours more 
conserved CTL epitopes that are identical in the PUUV N protein. However, as 
protein immunisation does normally not induce a lot of CTLs (discussed in chapter 
4.5), this explanations seems unlikely.  
For some enveloped viruses there is evidence that nucleocapsid specific 
antibodies can protect against a virus infection: p17-specific antibodies protected 
cells against HIV [Papsidero, 89], nucleocapsid specific antibodies against rabies 
virus [Lafon, 87] and against the Toscana virus, a representative of the genus 
Phlebovirus, family of Bunyaviridae [Cusi, 01]. For hantaviruses, it was shown in 
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vitro (VeroE6 cells) and in vivo (suckling mice model) that protection against 
infection can be mediated by N-specific mAbs from infection. Yoshimatsu did not 
measure the exact amount of antibodies used in passive transfer in the suckling 
mouse model [Yoshimatsu, 93] but did show some delay in death of mice 
challenged with HTNV that got passively transferred N-specific serum 
[Yoshimatsu, 96b]. In the same line, N-specific antibodies have been 
demonstrated to protect adult bank voles from a hantavirus infection (Lundkvist, 
personal communication). But, large amounts of mabs (0.5 mg) were needed for 
getting 50 % of animals protected and most of the N-specific mabs did not protect 
even when given in such a high amount (Lundkvist personal communication). The 
same level of protection was caused by passive transfer of spleen cells from mice 
immunised with HTN rN protein, which protected 43 % of suckling mice from an 
HTNV infection [Yoshimatsu, 93]. Therefore, protection against a hantavirus 
challenge induced by immunisation with N-constructs can partly be due to N-
specific antibodies.  
The mechanism by which antibodies specific for the internal N protein protect 
against the enveloped virus is not known. In the in vitro protection experiments 
mentioned above, the antibodies were scrape loaded onto the cells. Thereby, the 
N-specific antibodies can go into the cell and it was postulated that they inhibit 
uncoating or translation of the RNA [Yoshimatsu, 96a]. In vivo however, this 
mechanisms can not be imagined on big scale. ADCC was suggested as another 
potential protective mechanism for N-specific antibodies [de Carvalho Nicacio, 
01i], i.e. by binding of antibodies to cell surface located N protein and thereby 
marking these cells for destruction by NK cells. However, in contrast to the 
glycoproteins [Ogino, 04], N protein could not be found on the surface of HTNV 
infected cells [Yoshimatsu, 93]. As Old World hantaviruses are thought to bud at 
the Golgi compartment (see chapter 1.1) it is unlikely that N protein is located on 
the surface of PUUV infected cells.  
A possibly more likely explanation for the protection of N-specific antibodies 
against a hantavirus infection is the following. Antibodies bind to uncomplete 
virions, e.g. nucleocapsids, that are released by hantavirus infected cells and that 
these antibody/nucleocapsid complexes are more rapidly taken up by Fc receptor 
bearing APCs. These so called immune complexes might have been presented on 
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MHC class I and II better than protein alone [Rafiq, 02b]. Thereby nucleocapsid 
would be presented more rapidly and in bigger quantities on MHC class I and II to 
T cells. As the incubation time from hantavirus infection to outbreak of disease is 
relatively long (> 10 days), the rapid Fc dependent uptake of nucleocapsid protein 
leads to a more rapid and more vigorous T cell response that then can protect 
against the virus.  
Taken together, the immune response induced by HBcdDOB120 is similar to the 
immune response induced by DOBV rN protein as shown in this study. Thus, the 
immunological mechanisms induced by HBcdDOB120 and DOBV rN protein 
leading to protection against a hantavirus infection may be similar. The same 
derivatives based on PUUV rN protein induced protection against a hantavirus 
challenge. Immunisations with HBcdPUU120 protected 88 % (Lundkvist unpub. 
data) and PUUV rN protein protected 100% of bank voles agaisnt a PUUV 
challenge [Dargeviciute, 02]. The proteins used in this study should be tested in an 
DOBV challenge model. Suckling mice can be infected with DOBV [Klingström, 
03]. But, the immune system of suckling mice is not fully developed.. Recently it 
was shown that C57BL/6 mice might be used as a DOBV challenge model 
[Klingström, 04], even though the infection seems to be only transient. Thus both 
models are not ideal as a DOBV challenge model for the evaluation of vaccine 
candidates 
In conclusion it is not clear what kind of immune response is needed to fight 
hantaviruses, but it can be deduced from the studies mentioned above and the 
results from this investigation, that N-specific antibodies as well as T cells can play 
a role in protecting against a hantavirus infection. Further investigations are 
needed to address the question of which arm of the immune response is most 
important in protection against hantaviruses.  
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6 Appendix 
 
6.1 Abbreviations 
aa       amino acid 
ADCC antibody-dependent cytotoxicity 
ANDV Andes virus 
APC antigen presenting cell 
BSA bovine serum albumin 
CFA      complete Freund's adjuvant 
ConA concanavalin A 
CTL cytotoxic T cells 
DOBV Dobrava virus 
ELISA enzyme linked immunosorbent assay 
FCS      fetal calf serum 
G1, G2 hantavirus glycoproteins 1 and 2 
h hour 
HBc entire core protein of hepatitis B virus (aa 1-183) 
HBcd      carboxy-terminally truncated HBc (aa 1-144) 
HBV hepatitis B virus 
HCPS hantavirus cardiopulmonary syndrome 
HLA      human leukocyte antigen 
HFRS haemorrhagic fever with renal syndrome 
HTNV Hantaan virus 
HRP      horse radish peroxidase 
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IFA incomplete Freund's adjuvant 
IFN      interferon 
Ig      immunoglobulin 
IL      interleukin 
mAb monoclonal antibody 
MHC      major histocompability complex 
N nucleocapsid 
NE      nephropathia epidemica 
OD      optical density 
ORF      open reading frame 
PBS phosphor-buffered saline 
PUUV      Puumala virus 
RdRp RNA-dependent RNA polymerase 
rG2     recombinant glycoprotein 2 
rN      recombinant nucleocapsid 
sc      subcutaneous 
SEOV Seoul virus 
SI     stimulation index 
SNV Sin Nombre virus 
Th cell     T helper cell 
VLP      virus-like particle 
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